The 69th Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology MICEnavi

－____－________Opening Ceremony____－

OPEN

Opening Ceremony

TomW.Huizinga{HUIZINGATOMW.}|KeiIkeda{IKEDAKEI}|HarukaTsuchiya{TSUCHIYAHARUKA}|NaokiIwamoto{IWAMOTONAOKI}|MotomuHashimoto{HASHIMOTOMOTOMU}____AtsushiKawakami{KAWAKAMIATSUSHI}|TomW.Huizinga{HUIZINGATOMW.}________Symposium 1Clinical suspect arthralgia, Early arthritis and Early Rheumatoid arthritis____Glycobiology and maturation of AMPA during clinical suspect arthralgia to RA|Characteristics of clinically suspect arthralgia that progresses to inflammatory/rheumatoid arthritis|Omics analysis of synovial tissue opens up a new era for rheumatoid arthritis|Bone erosion and microarchitecture changes in inflammatory arthritis analyzed by HR-pQCT|Optimizing Molecular Targeted Therapies in Rheumatoid Arthritis: Insights from Registry Studies

S1

Symposium 1
Clinical suspect arthralgia, Early arthritis and Early Rheumatoid arthritis

Chair：Atsushi Kawakami, Chair：Tom W. Huizinga

Speaker：Tom W. Huizinga

Speaker：Kei Ikeda

Speaker：Haruka Tsuchiya

Speaker：Naoki Iwamoto

Speaker：Motomu Hashimoto

HidetoKameda{KAMEDAHIDETO}____YoshiyaTanaka{TANAKAYOSHIYA}________Luncheon Seminar 1Usefulness of IL-6 receptor inhibitors in the treatment of rheumatoid arthritis____Usefulness of IL-6 receptor inhibitors in the treatment of rheumatoid arthritis

LS1

Luncheon Seminar 1
Usefulness of IL-6 receptor inhibitors in the treatment of rheumatoid arthritis

【Sponsored by ASAHI KASEI PHARMA CORPORATION】

Chair：Yoshiya Tanaka

Speaker：Hideto Kameda

NaokiSawa{SAWANAOKI}|HironariHanaoka{HANAOKAHIRONARI}|HiroshiKajiyama{KAJIYAMAHIROSHI}|YujiNozaki{NOZAKIYUJI}|KunihiroIchinose{ICHINOSEKUNIHIRO}|HirokiHayashi{HAYASHIHIROKI}____NaokiSawa{SAWANAOKI}|HironariHanaoka{HANAOKAHIRONARI}____HarunaArai{ARAIHARUNA}|TakayaOzeki{OZEKITAKAYA}|ShoichiMaruyama{MARUYAMASHOICHI}____Symposium 2Nephrorheumatology: New insights into kidney disease of rheumatology____Establishment of the Concept of Nephro-Rheumatology|Chronic Kidney Disease in Rheumatology|Chronic kidney disease in rheumatoid arthritis ~ why kidney fails in patients with rheumatoid arthritis|Key Renal Pathological Features and Differences in Treatment Guidelines for ANCA-Associated Nephritis|Comprehensive Management Approaches for Preventing Chronic Kidney Disease Progression in Lupus Nephritis|IgG4-related disease and the kidney

S2

Symposium 2
Nephrorheumatology: New insights into kidney disease of rheumatology

Chair：Naoki Sawa, Chair：Hironari Hanaoka

Speaker：Naoki Sawa

Speaker：Hironari Hanaoka

Speaker：Hiroshi Kajiyama

Speaker：Yuji Nozaki

Speaker：Kunihiro Ichinose

Speaker：Hiroki Hayashi

YukiHara{HARAYUKI}|KiyotakeYoshioka{YOSHIOKAKIYOTAKE}|YosukeSakamoto{SAKAMOTOYOSUKE}|YuMatsueda{MATSUEDAYU}|AyanoAndo{ANDOAYANO}____ToruHirano{HIRANOTORU}|KosakuMurakami{MURAKAMIKOSAKU}____TakuroNii{NIITAKURO}|AkiraMiyama{MIYAMAAKIRA}|KoichiroTakahi{TAKAHIKOICHIRO}|HiroshiKida{KIDAHIROSHI}|YuMatsueda{MATSUEDAYU}|NaoTsugita{TSUGITANAO}|KeisukeIkeda{IKEDAKEISUKE}|YosukeSakamoto{SAKAMOTOYOSUKE}|YasuhiroHasegawa{HASEGAWAYASUHIRO}|TomokiTanaka{TANAKATOMOKI}|TatsuhikoWada{WADATATSUHIKO}|SumiakiTanaka{TANAKASUMIAKI}|KenjiOku{OKUKENJI}|KunihiroYamaoka{YAMAOKAKUNIHIRO}|AyanoAndo{ANDOAYANO}|KiyotakeYoshioka{YOSHIOKAKIYOTAKE}|YosukeIwadate{IWADATEYOSUKE}|NanaSugimoto{SUGIMOTONANA}|ShunsukeKyoda{KYODASHUNSUKE}|EriShishido{SHISHIDOERI}|HirotomoAsakura{ASAKURAHIROTOMO}|RisaShindo{SHINDORISA}____Workshop 1Comorbidities of rheumatic diseases 1____Analysis of Risk Factors for Exacerbation in Patients with Rheumatoid Arthritis and Interstitial Pneumonia|A Study on the Prognosis of Rheumatoid Arthritis Patients with Bronchiectasis|Efficacy of Tocilizumab for acute respiratory distress syndrome associated with connective tissue disease|Predictive Factors of Worsening in Interstitial Lung Disease Associated with Connective Tissue Disease Treated by Nintedanib|Long-term Prognosis of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease Treated with Combination Therapy of Pulmonary Arterial Hypertension Specific Drugs|The Benefit of Intensive Screening for Malignancies in Patients with Rheumatoid Arthritis

W1

Workshop 1
Comorbidities of rheumatic diseases 1

Chair：Toru Hirano, Chair：Kosaku Murakami

YukoKaneko{KANEKOYUKO}|TakeruSonoda{SONODATAKERU}|RyotaSakai{SAKAIRYOTA}|YoshiyaTanaka{TANAKAYOSHIYA}____HiroakiNiiro{NIIROHIROAKI}|KenjiOku{OKUKENJI}____EduardoMysler{MYSLEREDUARDO}|StanislavIgnatenko{IGNATENKOSTANISLAV}|AlexanderGordienko{GORDIENKOALEXANDER}|JosefinaCortés-Hernández{CORTÉS-HERNÁNDEZJOSEFINA}|NancyAgmon-Levin{AGMON-LEVINNANCY}|PongthornNarongroeknawin{NARONGROEKNAWINPONGTHORN}|KatarzynaRomanowska-Prochnicka{ROMANOWSKA-PROCHNICKAKATARZYNA}|NanShen{SHENNAN}|HanaHana{HANAHANA}|MasanariKodera{KODERAMASANARI}|JamesCheng-ChungWei{CHENG-CHUNGWEIJAMES}|PiotrLeszczynski{LESZCZYNSKIPIOTR}|JoungLiangLan{LIANGLANJOUNG}|RafalWojciechowski{WOJCIECHOWSKIRAFAL}|TundeTarr{TARRTUNDE}|ElenaVishneva{VISHNEVAELENA}|Yi-HsingChen{CHENYI-HSING}|StephanieFinzel{FINZELSTEPHANIE}|AlbertaHoi{HOIALBERTA}|MasatoOkada{OKADAMASATO}|AjcharaKoolvisoot{KOOLVISOOTAJCHARA}|Shin-SeokLee{LEESHIN-SEOK}|LieDai{DAILIE}|HiroshiKaneko{KANEKOHIROSHI}|BernadetteRojkovich{ROJKOVICHBERNADETTE}|LingyunSun{SUNLINGYUN}|EugenyZotkin{ZOTKINEUGENY}|Jean-FrançoisViallard{VIALLARDJEAN-FRANÇOIS}|BertaPaulaMagallares{PAULAMAGALLARESBERTA}|TirthaSengupta{SENGUPTATIRTHA}|SipsCarole{CAROLESIPS}|Lau{LAU}|AvrameasAlexandre{ALEXANDREAVRAMEAS}|StephenJ.{STEPHENJ.}|ShigeruIwata{IWATASHIGERU}|RyoMatsumiya{MATSUMIYARYO}|HideakiTsuji{TSUJIHIDEAKI}|AkiraOnishi{ONISHIAKIRA}|ToshihikoShiga{SHIGATOSHIHIKO}|YujiNozaki{NOZAKIYUJI}|HirofumiMiyake{MIYAKEHIROFUMI}|YumikoWada{WADAYUMIKO}|YuriHiramatsu{HIRAMATSUYURI}|MasaoKatsushima{KATSUSHIMAMASAO}|MotomuHashimoto{HASHIMOTOMOTOMU}|HidekiOka{OKAHIDEKI}|KoichiroOhmura{OHMURAKOICHIRO}|WataruYamamoto{YAMAMOTOWATARU}|TakaoFujii{FUJIITAKAO}|TakumiAoki{AOKITAKUMI}|TaijiKosaka{KOSAKATAIJI}|ShoichiYoshinaga{YOSHINAGASHOICHI}|AkikoShibata{SHIBATAAKIKO}|TakahikoKurasawa{KURASAWATAKAHIKO}|HironariHanaoka{HANAOKAHIRONARI}|KoichiAamano{AAMANOKOICHI}|BenjaminFisher{FISHERBENJAMIN}|HendrikaBootsma{BOOTSMAHENDRIKA}|VibekeStrand{STRANDVIBEKE}|Wan-FaiNg{NGWAN-FAI}|ThomasWegman{WEGMANTHOMAS}|BrandonBecker{BECKERBRANDON}|JiyoonChoi{CHOIJIYOON}|AntoineSreih{SREIHANTOINE}|LeoLeo{LEOLEO}|AntoniaChristodoulou{CHRISTODOULOUANTONIA}|EricF.Morand{MORANDERICF.}|EdwardM.Vital{VITALEDWARDM.}|CristinaArriens{ARRIENSCRISTINA}|J.MichelleKahlenberg{KAHLENBERGJ.MICHELLE}|MaryK.Crow{CROWMARYK.}|AmitSaxena{SAXENAAMIT}|YanhuaHu{HUYANHUA}|CoburnHobar{HOBARCOBURN}|IanM.Catlett{CATLETTIANM.}|AtsushiKumanogoh{KUMANOGOHATSUSHI}|TatsuyaAtsumi{ATSUMITATSUYA}|TomonoriIshii{ISHIITOMONORI}____Workshop 2Treatment of SLE____Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study (Encore presentation)|Long-term effects of tacrolimus and mycophenolate mofetil on renal function in patients with SLE - A study using ANSWER-SLE cohort -|Long-term Efficacy and Safety of Cyclophosphamide and Tacrolimus Combination Therapy for Lupus Nephritis as remission induction therapy|Clinical efficacy and patient-reported outcomes (PROs) in anti-Ro/Sjögren's Syndrome-Related Antigen A (SSA) antibody-positive (+) patients (pts) with active systemic lupus erythematosus (SLE) treated with deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in the phase 2 PAISLEY trial (Encore presentation)|Deconvolution of transcriptomics changes in patients treated with deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, reveals novel mechanistic effects of TYK2 inhibition in systemic lupus erythematosus (SLE) (Encore presentation)|Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus (Encore presentation)

W2

Workshop 2
Treatment of SLE

Chair：Hiroaki Niiro, Chair：Kenji Oku

GerdR.Burmester{BURMESTERGERDR.}____TakaoKoike{KOIKETAKAO}________Luncheon Seminar 2JAK inhibitors in the treatment of RA____Efficacy and Safety of JAK Inhibitors for the Management of Rheumatoid Arthritis: Structural and Clinical Remission With Filgotinib

LS2

Luncheon Seminar 2
JAK inhibitors in the treatment of RA

【Sponsored by Gilead Sciences K.K./Eisai Co.,Ltd.】

Chair：Takao Koike

Speaker：Gerd R. Burmester

YuheiFujisawa{FUJISAWAYUHEI}|YasuhiroHasegawa{HASEGAWAYASUHIRO}|NatsukoHara{HARANATSUKO}|ShotaroSuzuki{SUZUKISHOTARO}|TaroNishikawa{NISHIKAWATARO}|SatokoNozato{NOZATOSATOKO}____ShingoNakayamada{NAKAYAMADASHINGO}|YumiTsuchida{TSUCHIDAYUMI}____TomohiroKuwamoto{KUWAMOTOTOMOHIRO}|RyuWatanabe{WATANABERYU}|AkiraOnishi{ONISHIAKIRA}|HideakiTsuji{TSUJIHIDEAKI}|YumikoWada{WADAYUMIKO}|TakuyaKotani{KOTANITAKUYA}|YujiNozaki{NOZAKIYUJI}|KaoriIshimura{ISHIMURAKAORI}|KoichiroOhmura{OHMURAKOICHIRO}|HidekiOka{OKAHIDEKI}|HirofumiMiyake{MIYAKEHIROFUMI}|TakaoFujii{FUJIITAKAO}|ShigeruIwata{IWATASHIGERU}|WataruYamamoto{YAMAMOTOWATARU}|RyuheiIshihara{ISHIHARARYUHEI}|MasaoKatsushima{KATSUSHIMAMASAO}|KazuoFukumoto{FUKUMOTOKAZUO}|ShinsukeYamada{YAMADASHINSUKE}|MotomuHashimoto{HASHIMOTOMOTOMU}|KeisukeIkeda{IKEDAKEISUKE}|AyanoAndo{ANDOAYANO}|KiyotakeYoshioka{YOSHIOKAKIYOTAKE}|NaoTsugita{TSUGITANAO}|YosukeIwadate{IWADATEYOSUKE}|YosukeSakamoto{SAKAMOTOYOSUKE}|EriShishido{SHISHIDOERI}|HirotomoAsakura{ASAKURAHIROTOMO}|RisaShindo{SHINDORISA}|KazumaIno{INOKAZUMA}|TomokiTanaka{TANAKATOMOKI}|YuMatsueda{MATSUEDAYU}|TatsuhikoWada{WADATATSUHIKO}|KenjiOku{OKUKENJI}|KunihiroYamaoka{YAMAOKAKUNIHIRO}|YasuhiroKatsumata{KATSUMATAYASUHIRO}|NobuyukiEndo{ENDONOBUYUKI}|TakayasuAndo{ANDOTAKAYASU}|EtsushiToyofuku{TOYOFUKUETSUSHI}|KeiichiSakurai{SAKURAIKEIICHI}|MarikoMori{MORIMARIKO}|KoheiYoshioka{YOSHIOKAKOHEI}|YukikoTakakuwa{TAKAKUWAYUKIKO}|KumikoTonooka{TONOOKAKUMIKO}|MisatoKawakami{KAWAKAMIMISATO}|TakeshiSuzuki{SUZUKITAKESHI}|KazukoYamazaki{YAMAZAKIKAZUKO}|HirokoNagafuchi{NAGAFUCHIHIROKO}|SeidoOoka{OOKASEIDO}|MasaakiMori{MORIMASAAKI}|KimitoKawahata{KAWAHATAKIMITO}|KodaiUeno{UENOKODAI}|RyoMatsumiya{MATSUMIYARYO}|TakashiKato{KATOTAKASHI}|YutaShimomura{SHIMOMURAYUTA}|TakeruSonoda{SONODATAKERU}|KeijyuYamada{YAMADAKEIJYU}|MaiNakano{NAKANOMAI}|MasayasuKitano{KITANOMASAYASU}|ShinichiroTsunoda{TSUNODASHINICHIRO}____Workshop 3SLE (Belimumab)____Identification of factors associated with belimumab retention in systemic lupus erythematosus: The ANSWER-SLE Cohort Study|Evaluation of the Rate of Achievement of Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus Concomitant with Belimumab and Investigation of Predictive Factors|Treatment with Belimumab in Patients with Systemic Lupus Erythematosus: A Single-Center Observational Study|A survey of the use of belimumab for lupus nephritis and the factors influencing the renal outcomes|Safety and Steroid-sparing Effect of Belimumab in the Maintenance Therapy of SLE Patients|Long-Term Discontinuation of Belimumab in SLE after Achieving Low Disease Activity

W3

Workshop 3
SLE (Belimumab)

Chair：Shingo Nakayamada, Chair：Yumi Tsuchida

MasahiroTada{TADAMASAHIRO}|SayuriTakamura{TAKAMURASAYURI}|HirotakaYamada{YAMADAHIROTAKA}|YoichiNakayama{NAKAYAMAYOICHI}|KenjiOkumura{OKUMURAKENJI}|MasanoriSudo{SUDOMASANORI}____HirofumiShoda{SHODAHIROFUMI}|TakumiMatsumoto{MATSUMOTOTAKUMI}____YoshinariMatsumoto{MATSUMOTOYOSHINARI}|TatsuyaKoike{KOIKETATSUYA}|KenjiMamoto{MAMOTOKENJI}|TomoyukiNakamura{NAKAMURATOMOYUKI}|ShyoheiAnno{ANNOSHYOHEI}|TakahiroIida{IIDATAKAHIRO}|HitoshiGoto{GOTOHITOSHI}|RyosukeIto{ITORYOSUKE}|MasanoriSudo{SUDOMASANORI}|HiroyukiWada{WADAHIROYUKI}|DaisukeKobayashi{KOBAYASHIDAISUKE}|AsamiAbe{ABEASAMI}|HiroshiOtani{OTANIHIROSHI}|KiyoshiNakazono{NAKAZONOKIYOSHI}|AkiraMurasawa{MURASAWAAKIRA}|HajimeIshikawa{ISHIKAWAHAJIME}|SatoshiIto{ITOSATOSHI}|SadaoJinno{JINNOSADAO}|IkuShirasugi{SHIRASUGIIKU}|AkiraOnishi{ONISHIAKIRA}|KosakuMurakami{MURAKAMIKOSAKU}|YasutakaOkita{OKITAYASUTAKA}|KosukeEbina{EBINAKOSUKE}|TetsuItami{ITAMITETSU}|YujiNozaki{NOZAKIYUJI}|YumikoWada{WADAYUMIKO}|TohruTakeuchi{TAKEUCHITOHRU}|RyuWatanabe{WATANABERYU}|MotomuHashimoto{HASHIMOTOMOTOMU}|KazumaNishisaka{NISHISAKAKAZUMA}|YokoNose{NOSEYOKO}|MaiYamashita{YAMASHITAMAI}|IkukoNaka{NAKAIKUKO}|TakaichiOkano{OKANOTAKAICHI}|KeisukeNishimura{NISHIMURAKEISUKE}|YoUeda{UEDAYO}|ShoSendo{SENDOSHO}|MasanoriTsubosaka{TSUBOSAKAMASANORI}|ShinyaHayashi{HAYASHISHINYA}|RyotaHara{HARARYOTA}|HidehikoMakino{MAKINOHIDEHIKO}|YonsuSon{SONYONSU}|MasakiKatayama{KATAYAMAMASAKI}|WataruYamamoto{YAMAMOTOWATARU}|RyosukeKuroda{KURODARYOSUKE}|JunSaegusa{SAEGUSAJUN}|AyakaYoshikawa{YOSHIKAWAAYAKA}|MasaoKatsushima{KATSUSHIMAMASAO}|TakayukiFujii{FUJIITAKAYUKI}|KoichiMurata{MURATAKOICHI}|MasaoTanaka{TANAKAMASAO}|ShuichiMatsuda{MATSUDASHUICHI}|AkioMorinobu{MORINOBUAKIO}|TaichiHayashi{HAYASHITAICHI}|KentaroSuzuki{SUZUKIKENTARO}|SayuriTakamura{TAKAMURASAYURI}____Workshop 4biological DMARDs for RA treatment 1____Do the b/tsDMARDs increase weight and muscle mass in patients with rheumatoid arthritis from multicenter prospective observational PRESENT study?|Effectiveness of certolizumab pegol in patients with rheumatoid arthritis based on RF values|Analysis of the Therapeutic Effects of Shortening Tocilizumab Treatment Interval and Switching to Sarilumab: The ANSWER Cohort Study|Comparative Effectiveness of bDMARDs and JAK Inhibitors in Sustaining Remission after Discontinuation in Rheumatoid Arthritis: Insights from the ANSWER Cohort|A study on the efficacy and safety of ozoralizumab without MTX in our hospital|The clinical evaluation of rheumatoid arthritis patients' disease activity treated with infliximab using REMICHECK Q® (REMIQ) at our hospital

W4

Workshop 4
biological DMARDs for RA treatment 1

Chair：Hirofumi Shoda, Chair：Takumi Matsumoto

GerdR.Burmester{BURMESTERGERDR.}____MasayoshiHarigai{HARIGAIMASAYOSHI}________Evening Seminar 1Optimizing Treatment of RA: Achieving Treatment Goals with Upadacitinib____Optimizing Treatment of RA: Achieving Treatment Goals with Upadacitinib

ES1

Evening Seminar 1
Optimizing Treatment of RA: Achieving Treatment Goals with Upadacitinib

【Sponsored by AbbVie GK】

Chair：Masayoshi Harigai

Speaker：Gerd R. Burmester

TakumiFunatsu{FUNATSUTAKUMI}|SoshiTakahashi{TAKAHASHISOSHI}|KazuyaKishimoto{KISHIMOTOKAZUYA}|YukikoTakakuwa{TAKAKUWAYUKIKO}|MasatsuguKomagamine{KOMAGAMINEMASATSUGU}|RyoTanaka{TANAKARYO}____MasahiroTada{TADAMASAHIRO}____TakaichiOkano{OKANOTAKAICHI}|AlfonsoDelPeralFanjul{DELPERALFANJULALFONSO}|MaiYamashita{YAMASHITAMAI}|IkuShirasugi{SHIRASUGIIKU}|ShoSendo{SENDOSHO}|HirotakaYamada{YAMADAHIROTAKA}|KeisukeNishimura{NISHIMURAKEISUKE}|YoUeda{UEDAYO}|HiroshiMatsuoka{MATSUOKAHIROSHI}|JunSaegusa{SAEGUSAJUN}|MayaNakagawa{NAKAGAWAMAYA}|MasatakaNamiki{NAMIKIMASATAKA}|TakumiYamaoka{YAMAOKATAKUMI}|MotokoKatayama{KATAYAMAMOTOKO}|KatsuhikoYoneda{YONEDAKATSUHIKO}|SaoriHatachi{HATACHISAORI}|ShunichiKumagai{KUMAGAISHUNICHI}|KosakuMurakami{MURAKAMIKOSAKU}|AkiraOnishi{ONISHIAKIRA}|YukiEtani{ETANIYUKI}|TadashiOkano{OKANOTADASHI}|MotomuHashimoto{HASHIMOTOMOTOMU}|YuriHiramatsu{HIRAMATSUYURI}|MahiroYamamoto{YAMAMOTOMAHIRO}|YonsuSon{SONYONSU}|AkihiroTanaka{TANAKAAKIHIRO}|ChisatoAshida{ASHIDACHISATO}|DaisukeTomita{TOMITADAISUKE}|TetsuItami{ITAMITETSU}|ToshihikoShiga{SHIGATOSHIHIKO}|YujiNozaki{NOZAKIYUJI}|KojiKinoshita{KINOSHITAKOJI}|SeidoOoka{OOKASEIDO}|NobuyukiEndo{ENDONOBUYUKI}|TakayasuAndo{ANDOTAKAYASU}|ShotaroSuzuki{SUZUKISHOTARO}|KeiichiSakurai{SAKURAIKEIICHI}|MarikoMori{MORIMARIKO}|TakeshiSuzuki{SUZUKITAKESHI}|KazukoYamazaki{YAMAZAKIKAZUKO}|MegumiHiida{HIIDAMEGUMI}|HirokoNagafuchi{NAGAFUCHIHIROKO}|KumikoTonooka{TONOOKAKUMIKO}|KimitoKawahata{KAWAHATAKIMITO}|SariTaguchi{TAGUCHISARI}|MasatakaKomagamine{KOMAGAMINEMASATAKA}|TetsujiNaka{NAKATETSUJI}____Workshop 5DMARDs・NSAIDs・others for RA treatment 1____Fib-4 index is a risk factor for discontinuation of methotrexate therapy in rheumatoid arthritis patients|Effectiveness and safety of subcutaneous methotrexate for liver dysfunction caused by oral methotrexate|Methotrexate and Rheumatoid Arthritis: Efficacy and safety of subcutaneous injection versus oral-Analysis using the Kansai Multicenter ANSWER cohort-|Impact of Subcutaneous Methotrexate on Cumulative Medical Costs in Methotrexate-Naïve Rheumatoid Arthritis Patients|Evaluation of clinical efficacy and safety of metoject in rheumatoid arthritis|Mid- to long-term outcomes of daily administration of 1 mg folic acid for dose-dependent side effects of Methotrexate

W5

Workshop 5
DMARDs・NSAIDs・others for RA treatment 1

Chair：Masahiro Tada

TetsuyaFurukawa{FURUKAWATETSUYA}|MikitoSuzuki{SUZUKIMIKITO}|YoshihitoShima{SHIMAYOSHIHITO}|KodaiIto{ITOKODAI}|TaroHorino{HORINOTARO}|TakuyaTomokawa{TOMOKAWATAKUYA}____YoshihitoShima{SHIMAYOSHIHITO}____SeijiNishii{NISHIISEIJI}|YukoMinagawa{MINAGAWAYUKO}|KazuteruNoguchi{NOGUCHIKAZUTERU}|TakeoAbe{ABETAKEO}|MasaoTamura{TAMURAMASAO}|TeppeiHashimoto{HASHIMOTOTEPPEI}|NaotoAzuma{AZUMANAOTO}|YoheiIsomura{ISOMURAYOHEI}|ShinjiWatanabe{WATANABESHINJI}|KeinaYomono{YOMONOKEINA}|YukoOta{OTAYUKO}|YuichiroShirai{SHIRAIYUICHIRO}|MasatakaKuwana{KUWANAMASATAKA}|AkaneWatanabe{WATANABEAKANE}|SatoshiIto{ITOSATOSHI}|YujiAkiyama{AKIYAMAYUJI}|HidekataYasuoka{YASUOKAHIDEKATA}|TakahiroSeno{SENOTAKAHIRO}|YutakaKawahito{KAWAHITOYUTAKA}|KoichiroTakahi{TAKAHIKOICHIRO}|KojiIshii{ISHIIKOJI}|AtsushiKumanogoh{KUMANOGOHATSUSHI}|TatsuakiNaganawa{NAGANAWATATSUAKI}|RisaOhara{OHARARISA}|NaokiDosoden{DOSODENNAOKI}|MarikaSawada{SAWADAMARIKA}|YumiIto{ITOYUMI}|NatsukoWatanabe{WATANABENATSUKO}|AiUmeda{UMEDAAI}|KonomiAkamatsu{AKAMATSUKONOMI}|MegumiKurumizawa{KURUMIZAWAMEGUMI}|TakakoHashimoto{HASHIMOTOTAKAKO}|JoNishino{NISHINOJO}|SyusakuFukaya{FUKAYASYUSAKU}|ToruMichitsuji{MICHITSUJITORU}|KanakoKojima{KOJIMAKANAKO}|ToshiyukiAramaki{ARAMAKITOSHIYUKI}|NaokiIwamoto{IWAMOTONAOKI}|KaoruTerada{TERADAKAORU}|YukitakaUeki{UEKIYUKITAKA}|KatsumiEguchi{EGUCHIKATSUMI}|AtsushiKawakami{KAWAKAMIATSUSHI}____Workshop 6Novel Treatments and Improved Prognosis in Systemic Sclerosis____Efficacy of Rituximab on skin Sclerosis in Systemic Sclerosis: Long-term Follow-up up to 5 years and Cases of Recurrence|Mortality and causes of death in patients with systemic sclerosis (SSc)|Can the difference in grip strength between morning and evening express the morning stiffness observed in rheumatoid arthritis? An attempt to quantify the morning stiffness|Clinical characteristics of patients with Scleroderma (SSc) associated with the physical frailty|Antinuclear antibody patterns and coexisting autoimmune diseases in patients with centromere antibody-positive limited cutaneous systemic sclerosis|"A Case of Anti-RuvBL1/2 Antibody-Positive Systemic Sclerosis Complicated with Myositis and Interstitial Lung Disease"

W6

Workshop 6
Novel Treatments and Improved Prognosis in Systemic Sclerosis

Chair：Yoshihito Shima

KosukeEbina{EBINAKOSUKE}____TatsuyaAtsumi{ATSUMITATSUYA}________Luncheon Seminar 3Bone Metabolism Abnormalities in Rheumatic Diseases and Their Management : Insights for Rheumatologists Based on the Updated Guidelines for Glucocorticoid-Induced Osteoporosis____Bone Metabolism Abnormalities in Rheumatic Diseases and Their Management: Insights for Rheumatologists Based on the Updated Guidelines for Glucocorticoid-Induced Osteoporosis

LS3

Luncheon Seminar 3
Bone Metabolism Abnormalities in Rheumatic Diseases and Their Management : Insights for Rheumatologists Based on the Updated Guidelines for Glucocorticoid-Induced Osteoporosis

【Sponsored by DAIICHI SANKYO COMPANY, LIMITED】

Chair：Tatsuya Atsumi

Speaker：Kosuke Ebina

TakuyaHarada{HARADATAKUYA}|NatsukaUmezawa{UMEZAWANATSUKA}|AkiraYoshida{YOSHIDAAKIRA}|YohsukeOto{OTOYOHSUKE}|KenYoshida{YOSHIDAKEN}|NaokiMugii{MUGIINAOKI}____ShinjiSato{SATOSHINJI}|NaokiKimura{KIMURANAOKI}____HiroyukiYamashita{YAMASHITAHIROYUKI}|MayukoHayashi{HAYASHIMAYUKO}|YutaroMisawa{MISAWAYUTARO}|ArutoYamamoto{YAMAMOTOARUTO}|MiyuWakatsuki{WAKATSUKIMIYU}|YuyaAkiyama{AKIYAMAYUYA}|SetsukoOyama{OYAMASETSUKO}|KyokoMotomura{MOTOMURAKYOKO}|HiroyukiTakahashi{TAKAHASHIHIROYUKI}|YuichiGoto{GOTOYUICHI}|HideyoNoiri{NOIRIHIDEYO}|HiroshiKaneko{KANEKOHIROSHI}|MikuShimamura{SHIMAMURAMIKU}|MarinaKise{KISEMARINA}|RihanDa{DARIHAN}|ShinsukeYasuda{YASUDASHINSUKE}|TakahisaGono{GONOTAKAHISA}|YukaOkazaki{OKAZAKIYUKA}|TomoyukiFujisawa{FUJISAWATOMOYUKI}|MasatakaKuwana{KUWANAMASATAKA}|KenYoshida{YOSHIDAKEN}|TakeshiFukuda{FUKUDATAKESHI}|YoshinaoMuro{MUROYOSHINAO}|TaroUkichi{UKICHITARO}|KentaroNoda{NODAKENTARO}|KazuhiroOtani{OTANIKAZUHIRO}|DaitaroKurosaka{KUROSAKADAITARO}|EmiMinekawa{MINEKAWAEMI}|AiriMitsumori{MITSUMORIAIRI}|MasayoriMoriyama{MORIYAMAMASAYORI}|TakayukiMatsushita{MATSUSHITATAKAYUKI}|YohsukeOto{OTOYOHSUKE}|MitsuhiroKawano{KAWANOMITSUHIRO}|TakashiMatsushita{MATSUSHITATAKASHI}____Workshop 7Polymyositis and dermatomyositis: pathogenesis and imaging____Spatial Transcriptomics for Myositis: From GAPFREE4, an industry-academia-government collaborative project|Different roles of RasGRP1 and RasGPR4 in inflammatory myopathies|Stratification of anti-MDA5 antibody-positive dermatomyositis by type I/III interferons in circulation|The relationship between radiological myositis on skeletal muscle MRI and progressive fibrotic interstitial lung disease in anti-ARS antibody-positive patients|The characteristics of proximal muscle MRI findings in anti-TIF1 gamma antibody-positive dermatomyositis with cancer|Changes in muscle strength and muscle mass over time in patients with inflammatory myopathy

W7

Workshop 7
Polymyositis and dermatomyositis: pathogenesis and imaging

Chair：Shinji Sato, Chair：Naoki Kimura

KentaMisaki{MISAKIKENTA}|HirotoTsuboi{TSUBOIHIROTO}|SatoshiKubo{KUBOSATOSHI}____TatsuyaAtsumi{ATSUMITATSUYA}|HirofumiShoda{SHODAHIROFUMI}____NanaUematsu{UEMATSUNANA}|AkiyoshiRai{RAIAKIYOSHI}|HirofumiToko{TOKOHIROFUMI}|ToshikiSugita{SUGITATOSHIKI}|AyakoOhyama{OHYAMAAYAKO}|MasaruShimizu{SHIMIZUMASARU}|AyakoKitada{KITADAAYAKO}|SaoriAbe{ABESAORI}|HarukaMiki{MIKIHARUKA}|HiromitsuAsashima{ASASHIMAHIROMITSU}|YuyaKondo{KONDOYUYA}|IsaoMatsumoto{MATSUMOTOISAO}____Evening Seminar 2Current status and prospects of JAK inhibitors____The awesome achievement of Tofacitinib during the 12 years~The novel strategy for RA treatment to the future by Rheumatologist~|Positioning of JAK inhibitors for rheumatoid arthritis (RA) with pulmonary involvements leading to Difficult to treat (D2T) RA|Understanding the Safety Profile and Mechanisms of JAK Inhibitors

ES2

Evening Seminar 2
Current status and prospects of JAK inhibitors

【Sponsored by Pfizer】

Chair：Tatsuya Atsumi, Chair：Hirofumi Shoda

Speaker：Kenta Misaki

Speaker：Hiroto Tsuboi

Speaker：Satoshi Kubo

YoshiyaTanaka{TANAKAYOSHIYA}____ShigekiMomohara{MOMOHARASHIGEKI}________Educational Lecture 1Year in review, clinical____Year in review, clinical

EL1

Educational Lecture 1
Year in review, clinical

Chair：Shigeki Momohara

Lecturer：Yoshiya Tanaka

KeishiFujio{FUJIOKEISHI}____IsaoMatsumoto{MATSUMOTOISAO}________Educational Lecture 2Year in review (Basic)____Year in review (Basic)

EL2

Educational Lecture 2
Year in review (Basic)

Chair：Isao Matsumoto

Lecturer：Keishi Fujio

SatoshiKubo{KUBOSATOSHI}____KeiIkeda{IKEDAKEI}________Luncheon Seminar 4The role of JAK Inhibitors in rheumatoid arthritis: Insights from the FIRST registry____The role of JAK Inhibitors in rheumatoid arthritis: Insights from the FIRST registry

LS4

Luncheon Seminar 4
The role of JAK Inhibitors in rheumatoid arthritis: Insights from the FIRST registry

【Sponsored by AbbVie GK】

Chair：Kei Ikeda

Speaker：Satoshi Kubo

TetsuyaTomita{TOMITATETSUYA}____MichiakiTakagi{TAKAGIMICHIAKI}________Educational Lecture 3Frontiers in knee osteoarthritis treatment____Frontiers in knee osteoarthritis treatment

EL3

Educational Lecture 3
Frontiers in knee osteoarthritis treatment

Chair：Michiaki Takagi

Lecturer：Tetsuya Tomita

TakakoMiyamae{MIYAMAETAKAKO}____YutakaKawahito{KAWAHITOYUTAKA}________Educational Lecture 4Perspectives and Challenges of Telemedicine in Rheumatic Diseases: Insights from 'Recommendations for Establishing Online Medical Care for RA, JIA with Oligoarthritis or Polyarthritis, and SLE.'____Perspectives and Challenges of Telemedicine in Rheumatic Diseases: Insights from 'Recommendations for Establishing Online Medical Care for RA, JIA with Oligoarthritis or Polyarthritis, and SLE.'

EL4

Educational Lecture 4
Perspectives and Challenges of Telemedicine in Rheumatic Diseases: Insights from 'Recommendations for Establishing Online Medical Care for RA, JIA with Oligoarthritis or Polyarthritis, and SLE.'

Chair：Yutaka Kawahito

Lecturer：Takako Miyamae

AkioMorinobu{MORINOBUAKIO}____YutakaKawahito{KAWAHITOYUTAKA}________Evening Seminar 3Importance of Shingles (Herpes Zoster) Prevention in Rheumatic Diseases____Importance of Shingles (Herpes Zoster) Prevention in Rheumatic Diseases

ES3

Evening Seminar 3
Importance of Shingles (Herpes Zoster) Prevention in Rheumatic Diseases

【Sponsored by GlaxoSmithKline K.K.】

Chair：Yutaka Kawahito

Speaker：Akio Morinobu

Marie-ChristopheBoissier{BOISSIERMARIE-CHRISTOPHE}|DennisG.Mcgonagle{MCGONAGLEDENNISG.}|YasushiKondo{KONDOYASUSHI}|KosukeEbina{EBINAKOSUKE}|HidetoKameda{KAMEDAHIDETO}____HidetoKameda{KAMEDAHIDETO}|Marie-ChristopheBoissier{BOISSIERMARIE-CHRISTOPHE}____YukiEtani{ETANIYUKI}|TakaakiNoguchi{NOGUCHITAKAAKI}|SeijiOkada{OKADASEIJI}____Symposium 3Up-to-date pathogenesis, diagnosis and treatment challenges of arthritis and enthesitis____Environment and Exposome in Rheumatoid Arthritis|Pathogenesis of enthesitis and secondary synovitis|Recent progress and future potential in the imaging of inflammatory arthritis|Cutting-edge of the treatment of arthritis: Bridging the gap between RCTs and real-world clinical practice through cohort studies|Unmet needs in the current treatment of arthritis and enthesitis

S3

Symposium 3
Up-to-date pathogenesis, diagnosis and treatment challenges of arthritis and enthesitis

Chair：Hideto Kameda, Chair：Marie-Christophe Boissier

Speaker：Marie-Christophe Boissier

Speaker：Dennis G. Mcgonagle

Speaker：Yasushi Kondo

Speaker：Kosuke Ebina

Speaker：Hideto Kameda

Ken-EiSada{SADAKEN-EI}____NaotoTamura{TAMURANAOTO}________Luncheon Seminar 5Treatment for Eosinophilic granulomatosis with polyangiitis (EGPA): Up-to-date____Treatment for Eosinophilic granulomatosis with polyangiitis (EGPA): Up-to-date

LS5

Luncheon Seminar 5
Treatment for Eosinophilic granulomatosis with polyangiitis (EGPA): Up-to-date

【Sponsored by AstraZeneca K.K.】

Chair：Naoto Tamura

Speaker：Ken-Ei Sada

TakeshiJohkoh{JOHKOHTAKESHI}|TomonoriTanaka{TANAKATOMONORI}|TomoakiHiguchi{HIGUCHITOMOAKI}|TakahisaGono{GONOTAKAHISA}|MasaruKato{KATOMASARU}|TohruTakeuchi{TAKEUCHITOHRU}____YasushiKawaguchi{KAWAGUCHIYASUSHI}________Symposium 42025 guidelines for the diagnosis and treatment of interstitial lung disease associated with connective tissue diseases____Imaging of connective tissue diseases related intersting lung diseases|The importance of lung biopsy on interstitial lung disease associated with connective disease|Evaluation of connective tissue disease-associated interstitial lung disease|Myositis-associated interstitial lung disease|Interstitial lung disease associated with systemic sclerosis|Diagnosis and Treatment of Interstitial Lung Disease Associated with Rheumatoid Arthritis

S4

Symposium 4
2025 guidelines for the diagnosis and treatment of interstitial lung disease associated with connective tissue diseases

Chair：Yasushi Kawaguchi

Speaker：Takeshi Johkoh

Speaker：Tomonori Tanaka

Speaker：Tomoaki Higuchi

Speaker：Takahisa Gono

Speaker：Masaru Kato

Speaker：Tohru Takeuchi

ShunTanimura{TANIMURASHUN}|ShigekazuKurihara{KURIHARASHIGEKAZU}|TomoakiIda{IDATOMOAKI}|KotaroKomori{KOMORIKOTARO}|HirokazuTatsumi{TATSUMIHIROKAZU}|NaofumiDobashi{DOBASHINAOFUMI}____KotaShimada{SHIMADAKOTA}|NatsukaUmezawa{UMEZAWANATSUKA}____YusukeTabata{TABATAYUSUKE}|AkemiKitano{KITANOAKEMI}|YuheiShibata{SHIBATAYUHEI}|IkumaNakagawa{NAKAGAWAIKUMA}|MegumiMatsuhashi{MATSUHASHIMEGUMI}|MasatoShimizu{SHIMIZUMASATO}|KazuhideTanimura{TANIMURAKAZUHIDE}|TakaoKoike{KOIKETAKAO}|HisashiSugimoto{SUGIMOTOHISASHI}|YukiOba{OBAYUKI}|MasayukiYamanouchi{YAMANOUCHIMASAYUKI}|TatsuyaSuwabe{SUWABETATSUYA}|YoshifumiUbara{UBARAYOSHIFUMI}|NaokiSawa{SAWANAOKI}|ShunsukeFuruta{FURUTASHUNSUKE}|TaroIwamoto{IWAMOTOTARO}|YoshihisaKobayashi{KOBAYASHIYOSHIHISA}|TatsuroTakahashi{TAKAHASHITATSURO}|TomohiroTamachi{TAMACHITOMOHIRO}|MasahiroYasui{YASUIMASAHIRO}|HiroshiNakajima{NAKAJIMAHIROSHI}|HirokazuTatsumi{TATSUMIHIROKAZU}|HirokazuTaguchi{TAGUCHIHIROKAZU}|SairiTakahashi{TAKAHASHISAIRI}|NanaeOkimoto{OKIMOTONANAE}|YukiTerashima{TERASHIMAYUKI}|KeiKarakida{KARAKIDAKEI}|IsseiTakahashi{TAKAHASHIISSEI}|TomohiroKato{KATOTOMOHIRO}|AkaneIto{ITOAKANE}|YoshitakaUeda{UEDAYOSHITAKA}|EisukeTakamasu{TAKAMASUEISUKE}|KaeOnishi{ONISHIKAE}|YujiMiyoshi{MIYOSHIYUJI}|YoshikiNagai{NAGAIYOSHIKI}|NaotoYokogawa{YOKOGAWANAOTO}|KotaShimada{SHIMADAKOTA}|KotaroKomori{KOMORIKOTARO}|KeneiSada{SADAKENEI}____Workshop 8Rheumatic diseases and opportunistic infections____Preventive Efficacy of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients with Janus kinase inhibitors|Use of Recombinant Subunit Herpes Zoster Vaccine in Patients with Rheumatic Diseases|Low-dose atovaquone for prophylaxis of pneumocystis jirovecii pneumonia in rheumatic diseases patients treated with glucocorticoids: A single-arm, phase II trial|A case of Pneumocystis pneumonia developing during atovaquone prophylaxis in a patient with TAFRO syndrome|A case of refractory anti-MDA5 antibody-positive dermatomyositis with muscle abscess due to disseminated aspergillosis under the combination of cyclophosphamide, glucocorticoids, tacrolimus, and tofacitinib|The Impact of SGLT2 Inhibitors on the Risk of Urinary Tract Infections in Rheumatoid Arthritis Patients with Diabetes

W8

Workshop 8
Rheumatic diseases and opportunistic infections

Chair：Kota Shimada, Chair：Natsuka Umezawa

TakahiroNatori{NATORITAKAHIRO}|EriWatanabe{WATANABEERI}|KazuhiroOtani{OTANIKAZUHIRO}|SatoshiKanazawa{KANAZAWASATOSHI}|TakahiroNishino{NISHINOTAKAHIRO}|RieKomatsu{KOMATSURIE}____JunichiKikuta{KIKUTAJUNICHI}____HisakataYamada{YAMADAHISAKATA}|RyosukeTsurui{TSURUIRYOSUKE}|YukioAkasaki{AKASAKIYUKIO}|ToshifumiFujiwara{FUJIWARATOSHIFUMI}|RyosukeYamaguchi{YAMAGUCHIRYOSUKE}|DaisukeHara{HARADAISUKE}|YasuharuNakashima{NAKASHIMAYASUHARU}|JunkoNishio{NISHIOJUNKO}|ZentoYamada{YAMADAZENTO}|ToshihiroNanki{NANKITOSHIHIRO}|DaitaroKurosaka{KUROSAKADAITARO}|YokoMiura{MIURAYOKO}|MichihiroKono{KONOMICHIHIRO}|BunkiNatsumoto{NATSUMOTOBUNKI}|KazuyoshiIshigaki{ISHIGAKIKAZUYOSHI}|RyojiFujii{FUJIIRYOJI}|HisateruNiki{NIKIHISATERU}|KazuoYudoh{YUDOHKAZUO}____Workshop 9Basic rheumatology 1____Comparative analysis of CD8 T cells in rheumatoid arthritis and osteoarthritis|Analysis of cellular senescence in rheumatoid arthritis-associated interstitial lung disease using a mouse model|Inflammatory changes in the olfactory bulb related to food intake in a mouse model of arthritis correlate with changes in steroid-related factors in the hypothalamus|Identification of characteristic vascular endothelial cell population by a web-based integrative transcriptome analysis of CD146mid/high cells derived from pannus in RA mouse model|Establishment of infrastructure for large-scale T-cell receptor analysis to elucidate the pathogenesis of autoimmune diseases|Effect of CDK6 deficiency on synovial hyperplasia in collagen-induced arthritis mice

W9

Workshop 9
Basic rheumatology 1

Chair：Junichi Kikuta

MasakiShimizu{SHIMIZUMASAKI}|YoheiKirino{KIRINOYOHEI}____MasaakiMori{MORIMASAAKI}|ToshihideMimura{MIMURATOSHIHIDE}________Luncheon Seminar 6Future Prospects of Still‘s Disease Treatment – Treatment Strategies Aimed at Life Changes for Patients –____Future Prospects of Still's Disease Treatment Based on the History of sJIA|Future Prospects of Still's Disease Treatment from Latest AOSD Therapies

LS6

Luncheon Seminar 6
Future Prospects of Still‘s Disease Treatment – Treatment Strategies Aimed at Life Changes for Patients –

【Sponsored by NOVARTIS PHARMA K.K.】

Chair：Masaaki Mori, Chair：Toshihide Mimura

Speaker：Masaki Shimizu

Speaker：Yohei Kirino

MitsumasaKishimoto{KISHIMOTOMITSUMASA}|TakeoSato{SATOTAKEO}|ShokoTateishi{TATEISHISHOKO}|HirokoKanda{KANDAHIROKO}|YuriMatsubara{MATSUBARAYURI}|YusukeKamba{KAMBAYUSUKE}____TadashiOkano{OKANOTADASHI}|IppeiMiyagawa{MIYAGAWAIPPEI}____AndraBalanescu{BALANESCUANDRA}|MariaAntoniettaD'Agostino{ANTONIETTAD'AGOSTINOMARIA}|AlexisOgdie{OGDIEALEXIS}|PhilippSewerin{SEWERINPHILIPP}|YuDeng{DENGYU}|LinyuShi{SHILINYU}|YoshiyukiSugimoto{SUGIMOTOYOSHIYUKI}|ShengZhong{ZHONGSHENG}|YunzhaoYunzhao{YUNZHAOYUNZHAO}|RalphLippe{LIPPERALPH}|LaureGossec{GOSSECLAURE}|MegumiKishimoto{KISHIMOTOMEGUMI}|MayumiKomine{KOMINEMAYUMI}|KatsuyaNagatani{NAGATANIKATSUYA}|KojiroSato{SATOKOJIRO}|SayakaShibata{SHIBATASAYAKA}|AyumiYoshizaki{YOSHIZAKIAYUMI}|RyutaroTakeda{TAKEDARYUTARO}|KentaMakabe{MAKABEKENTA}|KumikoOhno{OHNOKUMIKO}|YasunoriOmata{OMATAYASUNORI}|TakumiMatsumoto{MATSUMOTOTAKUMI}|ShinichiSato{SATOSHINICHI}|SakaeTanaka{TANAKASAKAE}|KeishiFujio{FUJIOKEISHI}|HirokoKanda{KANDAHIROKO}|ShokoTateishi{TATEISHISHOKO}|ShigeyoshiTsuji{TSUJISHIGEYOSHI}|YukariOkubo{OKUBOYUKARI}|MasaoTamura{TAMURAMASAO}|SatomiKobayashi{KOBAYASHISATOMI}|YokoIshihara{ISHIHARAYOKO}|YoshinoriTaniguchi{TANIGUCHIYOSHINORI}|YuyaTakakubo{TAKAKUBOYUYA}|MitsumasaKishimoto{KISHIMOTOMITSUMASA}|ReiWatanabe{WATANABEREI}|TetsuyaTomita{TOMITATETSUYA}____Workshop 10Spondyloarthritis 1____Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified With Machine Learning Analytics Using Data From Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials (Encore)|Analysis of achievement of minimal disease activity (MDA) by molecular targeted drug for psoriatic arthritis|Evaluation Methods for Psoriatic Arthritis in Real-World Clinical Practice|Investigation of difficult-to-treat PsA in real-world clinical practice|Epidemiological Feature of the patients with Pustulotic arthro-osteitis in Japan through a nationwide survey|A case of SAPHO syndrome with bone destruction lesion in the cervical spine

W10

Workshop 10
Spondyloarthritis 1

Chair：Tadashi Okano, Chair：Ippei Miyagawa

MakotoSugihara{SUGIHARAMAKOTO}|TomonoriIshii{ISHIITOMONORI}|HiromichiTamaki{TAMAKIHIROMICHI}|SariHoriuchi{HORIUCHISARI}|ToshioKawamoto{KAWAMOTOTOSHIO}|TakumiNagamoto{NAGAMOTOTAKUMI}____TsuyoshiShirai{SHIRAITSUYOSHI}|HajimeYoshifuji{YOSHIFUJIHAJIME}____EisukeTakamasu{TAKAMASUEISUKE}|NaofumiChinen{CHINENNAOFUMI}|MasahiroIida{IIDAMASAHIRO}|SayakaKoizumi{KOIZUMISAYAKA}|ShokoKimura{KIMURASHOKO}|NaotoYokogawa{YOKOGAWANAOTO}|KotaShimada{SHIMADAKOTA}|DanielBlockmans{BLOCKMANSDANIEL}|HiromichiTamaki{TAMAKIHIROMICHI}|SaraK.Penn{PENNSARAK.}|ArathiSetty{SETTYARATHI}|WolfgangA.Schmidt{SCHMIDTWOLFGANGA.}|AndreaRubbert-Roth{RUBBERT-ROTHANDREA}|MengLiu{LIUMENG}|WeihanZhao{ZHAOWEIHAN}|IvanIvan{IVANIVAN}|AnaB.Romero{ROMEROANAB.}|PeterA.Merkel{MERKELPETERA.}|RicardoBlanco{BLANCORICARDO}|RaviSuppiah{SUPPIAHRAVI}|ThomasDaikeler{DAIKELERTHOMAS}|ValerieDevauchelle-Pensec{DEVAUCHELLE-PENSECVALERIE}|ElisabethBrouwer{BROUWERELISABETH}|YangYang{YANGYANG}|AvaniJoshi{JOSHIAVANI}|CharlesPhillips{PHILLIPSCHARLES}|CristinaPonte{PONTECRISTINA}|TakahikoSugihara{SUGIHARATAKAHIKO}|YoshikazuNakaoka{NAKAOKAYOSHIKAZU}|RyokoSakai{SAKAIRYOKO}|MichihiroOgasawara{OGASAWARAMICHIHIRO}|KyuutaKato{KATOKYUUTA}|YuukoMuramoto{MURAMOTOYUUKO}|MarikoHarada{HARADAMARIKO}|EriHayashi{HAYASHIERI}|MasakazuMatsushita{MATSUSHITAMASAKAZU}|KenYamaji{YAMAJIKEN}|NaotoTamura{TAMURANAOTO}|SyunpeiSuzuki{SUZUKISYUNPEI}|ErihoYamaguchi{YAMAGUCHIERIHO}|KoheiYo{YOKOHEI}|YuriNishida{NISHIDAYURI}|HiroyukiMurabe{MURABEHIROYUKI}____Workshop 11Large vessel vasculitis____Elucidating the Molecular Mechanisms of Tissue Remodeling in Giant Cell Arteritis: Integration of Single-Cell Analysis and In Situ Gene Expression Data|Efficacy and Safety of Upadacitinib in Patients With Giant Cell Arteritis (SELECT-GCA): A Double-Blind, Randomized Controlled Phase 3 Trial: Overall Results and Sub-Analysis of Japanese Subjects|Efficacy of Upadacitinib in Patients With Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial (encore presentation)|Risk factors of serious infections in patients with giant cell arteritis|Characteristics of vascular ultrasound findings and transitions to the temporal artery in giant cell arteritis|Examination of factors with poor long-term life prognosis in Takayasu arteritis

W11

Workshop 11
Large vessel vasculitis

Chair：Tsuyoshi Shirai, Chair：Hajime Yoshifuji

KimitoKawahata{KAWAHATAKIMITO}|TakaoFujii{FUJIITAKAO}____IsaoMatsumoto{MATSUMOTOISAO}________Evening Seminar 4Latest Treatment Strategies for Systemic Lupus Erythematosus____The Role of Anifrolumab in the New Paradigm of Systemic Lupus Erythematosus Treatment: A Perspective on the Involvement of Type I IFN in Disease Pathogenesis|Unmet medical needs of SLE and expectations for anifrolumab

ES4

Evening Seminar 4
Latest Treatment Strategies for Systemic Lupus Erythematosus

【Sponsored by AstraZeneca K.K.】

Chair：Isao Matsumoto

Speaker：Kimito Kawahata

Speaker：Takao Fujii

AyakaUmetsu{UMETSUAYAKA}|ChiharuMiyamoto{MIYAMOTOCHIHARU}|YumiIto{ITOYUMI}|ShodaiTateyama{TATEYAMASHODAI}|HirotoTomoda{TOMODAHIROTO}|AkariMiwa-Shibahara{MIWA-SHIBAHARAAKARI}____TadashiHosoya{HOSOYATADASHI}____TomohiroKoga{KOGATOMOHIRO}|RemiSumiyoshi{SUMIYOSHIREMI}|TakashiJubashi{JUBASHITAKASHI}|HiroyukiShirahige{SHIRAHIGEHIROYUKI}|EikoKawakami{KAWAKAMIEIKO}|SerinaKoto{KOTOSERINA}|KazusatoHara{HARAKAZUSATO}|TomohisaUchida{UCHIDATOMOHISA}|MizunaOtsuka{OTSUKAMIZUNA}|YoshikaTsuji{TSUJIYOSHIKA}|ToshimasaShimizu{SHIMIZUTOSHIMASA}|MasatakaUmeda{UMEDAMASATAKA}|ShoichiFukui{FUKUISHOICHI}|Shin-YaKawashiri{KAWASHIRISHIN-YA}|NaokiIwamoto{IWAMOTONAOKI}|TahashiIgawa{IGAWATAHASHI}|MamiTamai{TAMAIMAMI}|TomokiOriguchi{ORIGUCHITOMOKI}|YasufumiMasaki{MASAKIYASUFUMI}|NaokiSawa{SAWANAOKI}|YukoKaneko{KANEKOYUKO}|MasayasuKitano{KITANOMASAYASU}|HiroakiNiiro{NIIROHIROAKI}|HajimeYoshifuju{YOSHIFUJUHAJIME}|AtsushiKawakami{KAWAKAMIATSUSHI}|ShintaroYasui{YASUISHINTARO}|YukinaTanimoto{TANIMOTOYUKINA}|TaisukeFujita{FUJITATAISUKE}|MichioMugitani{MUGITANIMICHIO}|KodaiYamamoto{YAMAMOTOKODAI}|HirotakaYamada{YAMADAHIROTAKA}|TakaichiOkano{OKANOTAKAICHI}|KeisukeNishimura{NISHIMURAKEISUKE}|ShoSendo{SENDOSHO}|YoUeda{UEDAYO}|JunSaegusa{SAEGUSAJUN}|RisaOhara{OHARARISA}|HarunaTakase{TAKASEHARUNA}|NaokiDosoden{DOSODENNAOKI}|KodaiIto{ITOKODAI}|MarikaSawada{SAWADAMARIKA}|NatsukoWatanabe{WATANABENATSUKO}|TatsuakiNaganawa{NAGANAWATATSUAKI}|AiUmeda{UMEDAAI}|KonomiAkamatsu{AKAMATSUKONOMI}|MegumiKurumizawa{KURUMIZAWAMEGUMI}|TakakoHashimoto{HASHIMOTOTAKAKO}|JoNishino{NISHINOJO}|SyusakuFukaya{FUKAYASYUSAKU}|HidekataYasuoka{YASUOKAHIDEKATA}|AyakaKato{KATOAYAKA}|MotochikaAsano{ASANOMOTOCHIKA}|IchiroMori{MORIICHIRO}|HiroyukiMorita{MORITAHIROYUKI}|NaruhikoAoyama{AOYAMANARUHIKO}|RyoheiNagata{NAGATARYOHEI}|Fang-YiChen{CHENFANG-YI}|KeigoSetoguchi{SETOGUCHIKEIGO}|JunKikuchi{KIKUCHIJUN}|ShoIshigaki{ISHIGAKISHO}|YasushiKondo{KONDOYASUSHI}|HiroshiTakei{TAKEIHIROSHI}|MitsuhiroAkiyama{AKIYAMAMITSUHIRO}|HironariHanaoka{HANAOKAHIRONARI}____Workshop 12Pathophysiology and Treatment Approaches for Castleman Disease and TAFRO Syndrome____Treatment responsiveness and prognostic predictors in idiopathic multicentric Castleman's disease and TAFRO Syndrome|Treatment Course of TAFRO Syndrome and Considerations in ProlongedThrombocytopenia: A Case Series of 7 Patients|Clinical features and long-term treatment course of TAFRO syndrome|An Observational Study of the Onset of Response to Combination Therapy with Prednisolone and Cyclosporine in TAFRO Syndrome and the Number of Days to Platelet and Serum CRP Normalization|Long-term efficacy and safety of tocilizumab in patients with idiopathic multicentric Castleman disease: a single-center cohort study|Successful Treatment of Two Cases of Idiopathic Multicentric Castleman Disease Complicated by IgA Vasculitis with Tocilizumab

W12

Workshop 12
Pathophysiology and Treatment Approaches for Castleman Disease and TAFRO Syndrome

Chair：Tadashi Hosoya

TasukuTogashi{TOGASHITASUKU}|ToshiyukiAramaki{ARAMAKITOSHIYUKI}|AkiraFurusaki{FURUSAKIAKIRA}|IkukoOnishi{ONISHIIKUKO}|ToshihikoHidaka{HIDAKATOSHIHIKO}|YukitakaUeki{UEKIYUKITAKA}____KeiIkeda{IKEDAKEI}____RyuWatanabe{WATANABERYU}|KoichiMurata{MURATAKOICHI}|AkiraOnishi{ONISHIAKIRA}|YasutakaOkita{OKITAYASUTAKA}|IkuShirasugi{SHIRASUGIIKU}|IkukoNaka{NAKAIKUKO}|YumikoWada{WADAYUMIKO}|MahiroYamamoto{YAMAMOTOMAHIRO}|YonsuSon{SONYONSU}|NaofumiYoshida{YOSHIDANAOFUMI}|YujiNozaki{NOZAKIYUJI}|TetsuItami{ITAMITETSU}|WataruYamamoto{YAMAMOTOWATARU}|YuyaYano{YANOYUYA}|RyuheiIshihara{ISHIHARARYUHEI}|MasaoKatsushima{KATSUSHIMAMASAO}|YuheiFujisawa{FUJISAWAYUHEI}|KazuoFukumoto{FUKUMOTOKAZUO}|ShinsukeYamada{YAMADASHINSUKE}|MotomuHashimoto{HASHIMOTOMOTOMU}|TakuyaTomokawa{TOMOKAWATAKUYA}|KanakoKojima{KOJIMAKANAKO}|ToruMichitsuji{MICHITSUJITORU}|AyukoTakatani{TAKATANIAYUKO}|KaoruTerada{TERADAKAORU}|NaokiIwamoto{IWAMOTONAOKI}|KatsumiEguchi{EGUCHIKATSUMI}|YukitakaUeki{UEKIYUKITAKA}|AtsumiKawakami{KAWAKAMIATSUMI}|IzumiYasuda{YASUDAIZUMI}|AkiraSagawa{SAGAWAAKIRA}|MasayukiInoo{INOOMASAYUKI}|RyoukoKagawa{KAGAWARYOUKO}|KentarouSusaki{SUSAKIKENTAROU}|KenichirouMatoba{MATOBAKENICHIROU}|SatoshiToudou{TOUDOUSATOSHI}|YayoiHashiba{HASHIBAYAYOI}|HarukaSasaki{SASAKIHARUKA}|KazuyoshiKubo{KUBOKAZUYOSHI}|AtsushiMatsuoka{MATSUOKAATSUSHI}|HiroshiKuroda{KURODAHIROSHI}|ToshiyukiAramaki{ARAMAKITOSHIYUKI}|AtushiKawakami{KAWAKAMIATUSHI}____Workshop 13biological DMARDs for RA treatment 2____Comparative Analysis of Ozoralizumab and Certolizumab Pegol in Patients with Rheumatoid Arthritis: Insights from the ANSWER Cohort|Tocilizumab injection spacing in patients with rheumatoid arthritis in daily clinical practice|Efficacy in patients with rheumatoid arthritis treated ozoralizumab in daily clinical practice (Second Report)|Effect of ozoralizumab in elderly patients with Rheumatoid arthritis|Comparison of the effects of sarilumab and JAK inhibitors on PRO in patients with rheumatoid arthritis: 1-year evaluation using RAPID3|A study on the selection of b/tsDMARDs for rheumatoid arthritis patients in our hospital

W13

Workshop 13
biological DMARDs for RA treatment 2

Chair：Kei Ikeda

RyuWatanabe{WATANABERYU}|KoichiroYano{YANOKOICHIRO}____KazuhisaNakano{NAKANOKAZUHISA}|NobunoriTakahashi{TAKAHASHINOBUNORI}________Luncheon Seminar 7The real world of JAK inhibitors____Tofacitinib in the treatment of rheumatoid arthritis*: Insights from the real world data|Perioperative Management of Molecular Targeted Agents: Establishing Appropriate Drug Withdrawal Periods

LS7

Luncheon Seminar 7
The real world of JAK inhibitors

【Sponsored by Pfizer】

Chair：Kazuhisa Nakano, Chair：Nobunori Takahashi

Speaker：Ryu Watanabe

Speaker：Koichiro Yano

MasanobuHorikoshi{HORIKOSHIMASANOBU}|TakakoSaeki{SAEKITAKAKO}|KazuoFukumoto{FUKUMOTOKAZUO}|TomohiroKato{KATOTOMOHIRO}|KanakoChujo{CHUJOKANAKO}|YoshiyaTanaka{TANAKAYOSHIYA}____MitsuhiroKawano{KAWANOMITSUHIRO}____KahoTakahashi{TAKAHASHIKAHO}|KeiichirouKanai{KANAIKEIICHIROU}|MasahiroYokosawa{YOKOSAWAMASAHIRO}|IchiroMizushima{MIZUSHIMAICHIRO}|YoshinoriTaniguchi{TANIGUCHIYOSHINORI}|YoshifumiUbara{UBARAYOSHIFUMI}|MitsuhiroKawano{KAWANOMITSUHIRO}|TasukuTogashi{TOGASHITASUKU}|YuyaYano{YANOYUYA}|RyuheiIshihara{ISHIHARARYUHEI}|MasaoKatsushima{KATSUSHIMAMASAO}|YuheiFujisawa{FUJISAWAYUHEI}|RyuWatanabe{WATANABERYU}|ShinsukeYamada{YAMADASHINSUKE}|MotomuHashimoto{HASHIMOTOMOTOMU}|KotaShimada{SHIMADAKOTA}|NanaeOkimoto{OKIMOTONANAE}|KazuhikoHirokawa{HIROKAWAKAZUHIKO}|KeisukeHirobe{HIROBEKEISUKE}|YukiTerashima{TERASHIMAYUKI}|IsseiTakahashi{TAKAHASHIISSEI}|EisukeTakamasu{TAKAMASUEISUKE}|MasakoUtsunomiya{UTSUNOMIYAMASAKO}|YoshikiNagai{NAGAIYOSHIKI}|NaotoYokogawa{YOKOGAWANAOTO}|HiromiShimada{SHIMADAHIROMI}|TaichiMiyagi{MIYAGITAICHI}|YusukeUshio{USHIOYUSUKE}|KoichiSugihara{SUGIHARAKOICHI}|RinaMino{MINORINA}|MaoMizusaki{MIZUSAKIMAO}|NaotoManabe{MANABENAOTO}|MayukoWada{WADAMAYUKO}|ShusakuNakashima{NAKASHIMASHUSAKU}|HirokiOzaki{OZAKIHIROKI}|RisaWakiya{WAKIYARISA}|HiroakiDobashi{DOBASHIHIROAKI}|CoryA.Perugino{PERUGINOCORYA.}|ZacharyS.Wallace{WALLACEZACHARYS.}|DebraJ.Zack{ZACKDEBRAJ.}|ShaunaM.Quinn{QUINNSHAUNAM.}|AllenPoma{POMAALLEN}|AnaD.Fernandes{FERNANDESANAD.}|PaulFoster{FOSTERPAUL}|SteveDemattos{DEMATTOSSTEVE}|BartBart{BARTBART}|HangLiu{LIUHANG}|HuguesAllard-Chamard{ALLARD-CHAMARDHUGUES}|NathanSmith{SMITHNATHAN}|XinKai{KAIXIN}|KellyXing{XINGKELLY}|ShivPillai{PILLAISHIV}|JohnH.Stone{STONEJOHNH.}____Workshop 14IgG4-related diseases: treatment____Efficacy of Azathioprine as Maintenance Therapy for IgG4-Related Disease|Hypocomplementemia in IgG4-related kidney disease (IgG4-RKD) is associated with rapid improved renal function after glucocorticoid induction therapy|Factors associated with relapse in 45 patients with IgG4-related disease in our department|Clinical course of six cases of IgG4-related disease treated with rituximab|Clinical characteristics and outcomes of IgG4-related disease without therapeutic intervention|Evaluation of the Safety, Efficacy, and Mechanism of Action of Obexelimab for the Treatment of Patients with IgG4-Related Disease: An Open-Label, Single-Arm, Single-Centre, Phase 2 Pilot Trial (Encore presentation)

W14

Workshop 14
IgG4-related diseases: treatment

Chair：Mitsuhiro Kawano

AkikoShibata{SHIBATAAKIKO}|MoeYamada{YAMADAMOE}|KodaiUeno{UENOKODAI}|ShunichiroHanai{HANAISHUNICHIRO}|HideyukiOkada{OKADAHIDEYUKI}|MaoMizusaki{MIZUSAKIMAO}____ShinsukeYasuda{YASUDASHINSUKE}|HironariHanaoka{HANAOKAHIRONARI}____TakumiAoki{AOKITAKUMI}|TaijiKosaka{KOSAKATAIJI}|ShoichiYoshinaga{YOSHINAGASHOICHI}|RyotaSakai{SAKAIRYOTA}|TakahikoKurasawa{KURASAWATAKAHIKO}|HironariHanaoka{HANAOKAHIRONARI}|KoichiAmano{AMANOKOICHI}|YuyaKondo{KONDOYUYA}|KotomiMurata{MURATAKOTOMI}|MamiYoshida{YOSHIDAMAMI}|FumiyukiShibasaki{SHIBASAKIFUMIYUKI}|TomonoriHishinuma{HISHINUMATOMONORI}|NanaUematsu{UEMATSUNANA}|FuminaKawashima{KAWASHIMAFUMINA}|ToshikiSugita{SUGITATOSHIKI}|MasaruShimizu{SHIMIZUMASARU}|AyakoOhyama{OHYAMAAYAKO}|SaoriAbe{ABESAORI}|AyakoKitada{KITADAAYAKO}|HiromitsuAsashima{ASASHIMAHIROMITSU}|HarukaMiki{MIKIHARUKA}|HirotoTsuboi{TSUBOIHIROTO}|IsaoMatsumoto{MATSUMOTOISAO}|SigeruIwata{IWATASIGERU}|RyoMatsumiya{MATSUMIYARYO}|TakashiKato{KATOTAKASHI}|YutaShimomura{SHIMOMURAYUTA}|TakeruSonoda{SONODATAKERU}|TaroNishikawa{NISHIKAWATARO}|TakaoFujii{FUJIITAKAO}|MoeWatanabe{WATANABEMOE}|SoichiroKubota{KUBOTASOICHIRO}|KojiroIkeda{IKEDAKOJIRO}|YoshiakiKobayashi{KOBAYASHIYOSHIAKI}|DaikiNakagomi{NAKAGOMIDAIKI}|YoshihiroUno{UNOYOSHIHIRO}|MamiIida{IIDAMAMI}|RisaWakiya{WAKIYARISA}|YusukeUshio{USHIOYUSUKE}|KoichiSugihara{SUGIHARAKOICHI}|RinaMino{MINORINA}|KanakoChujo{CHUJOKANAKO}|NaotoManabe{MANABENAOTO}|MayukoWada{WADAMAYUKO}|ShusakuNakashima{NAKASHIMASHUSAKU}|TaichiMiyagi{MIYAGITAICHI}|HiromiShimada{SHIMADAHIROMI}|HiroakiDobashi{DOBASHIHIROAKI}____Workshop 15SLE (Anifrolumab)____The efficacy and glucocorticoid dose-reduction effect of anifrolumab in patients with systemic lupus erythematosus|Clinical Characters in Patients with Systemic Lupus Erythematosus treated with Anifrolumab|Effectiveness of Glucocorticoid-Sparing Effect of Anifrolumab (ANF) in Maintenance Therapy in Systemic Lupus Erythematosus (SLE) Patients|Switching from belimumab to anifrolumab in patients with systemic lupus erythematosus: real world use and efficacy|Investigation of clinical predictors at the start of anifrolumab treatment associated with fatigue at 24 weeks after treatment for SLE|Current status of anifrolumab treatment for systemic lupus erythematosus at our hospital

W15

Workshop 15
SLE (Anifrolumab)

Chair：Shinsuke Yasuda, Chair：Hironari Hanaoka

KazunobuIchikawa{ICHIKAWAKAZUNOBU}|AkioMorinobu{MORINOBUAKIO}|NamiOkamoto{OKAMOTONAMI}|HidekiTsuboi{TSUBOIHIDEKI}|NatsukoNakagawa{NAKAGAWANATSUKO}|TatsuyaAtsumi{ATSUMITATSUYA}____YuyaTakakubo{TAKAKUBOYUYA}|RanNakashima{NAKASHIMARAN}____SakikoAshitomi{ASHITOMISAKIKO}|YutoNakakubo{NAKAKUBOYUTO}|YukoSugita{SUGITAYUKO}|KayoHira{HIRAKAYO}____Special Symposium 1Toward a Bright Future for Rheumatology -Is the promotion of Diversity, Equity, and Inclusion sufficient?-____－|Opening Remarks|Closing Remarks

SS1

Special Symposium 1
Toward a Bright Future for Rheumatology -Is the promotion of Diversity, Equity, and Inclusion sufficient?-

Chair：Yuya Takakubo, Chair：Ran Nakashima

Opening Remarks：Natsuko Nakagawa

Speaker：Kazunobu Ichikawa

Speaker：Akio Morinobu

Speaker：Nami Okamoto

Speaker：Hideki Tsuboi

Closing Remarks：Tatsuya Atsumi

YasushiKondo{KONDOYASUSHI}____TakaoFujii{FUJIITAKAO}________Luncheon Seminar 8Better treatment for more patients! ~Making the option of a biosimilar more accessible~____Better treatment for more patients! ~Making the option of a biosimilar more accessible~

LS8

Luncheon Seminar 8
Better treatment for more patients! ~Making the option of a biosimilar more accessible~

【Sponsored by AYUMI Pharmaceutical Corporation】

Chair：Takao Fujii

Speaker：Yasushi Kondo

YukoKaneko{KANEKOYUKO}|NobunoriTakahashi{TAKAHASHINOBUNORI}|TakahikoSugihara{SUGIHARATAKAHIKO}|HidetoKameda{KAMEDAHIDETO}|YuyaTakakubo{TAKAKUBOYUYA}|HiromuIto{ITOHIROMU}____IsaoMatsushita{MATSUSHITAISAO}|AkioMorinobu{MORINOBUAKIO}____YoshihiroWanezaki{WANEZAKIYOSHIHIRO}|MichiakiTakagi{TAKAGIMICHIAKI}|KoichiMurata{MURATAKOICHI}|ShuichiMatsuda{MATSUDASHUICHI}____Symposium 5Thinking about Unmet-Needs in Rheumatoid Arthritis Treatment To Maximize Quality of Life of the Patients____The importance of patient-reported outcomes in clinical practice|The Importance of Early Treatment in Difficult-to-Treat Rheumatoid Arthritis (D2T-RA)|Evidence and practice of treatment of older rheumatoid arthritis patients|Management of patients with RA and other complications|Rheumatology rehabilitation treatment aimed at maximizing QOL|Toward expansion of the range of QOL -Orthopaedic surgery-

S5

Symposium 5
Thinking about Unmet-Needs in Rheumatoid Arthritis Treatment To Maximize Quality of Life of the Patients

Chair：Isao Matsushita, Chair：Akio Morinobu

Speaker：Yuko Kaneko

Speaker：Nobunori Takahashi

Speaker：Takahiko Sugihara

Speaker：Hideto Kameda

Speaker：Yuya Takakubo

Speaker：Hiromu Ito

－|YoshitakaHamada{HAMADAYOSHITAKA}|NatsukoNakagawa{NAKAGAWANATSUKO}____KeiichiroNishida{NISHIDAKEIICHIRO}|TakujiIwamoto{IWAMOTOTAKUJI}|RyoOda{ODARYO}|MasanoriNakayama{NAKAYAMAMASANORI}|HajimeIshikawa{ISHIKAWAHAJIME}|YoshitakaHamada{HAMADAYOSHITAKA}________Evening Seminar 5____－|Hand Surgery for D2T RA|Drug treatment and hand surgery for D2TRA

ES5

Evening Seminar 5

【Sponsored by Chugai Pharmaceutical Co., Ltd.】

Chair：Keiichiro Nishida, Chair：Takuji Iwamoto, Panelist：Ryo Oda, Panelist：Masanori Nakayama, Panelist：Hajime Ishikawa, Chair：Yoshitaka Hamada

Speaker：Yoshitaka Hamada

Speaker：Natsuko Nakagawa

ShinichiNogi{NOGISHINICHI}|YuheiFujisawa{FUJISAWAYUHEI}|FumihiroIto{ITOFUMIHIRO}|SumiakiTanaka{TANAKASUMIAKI}|YutaShimomura{SHIMOMURAYUTA}|TetsuItami{ITAMITETSU}____ShinyaHayashi{HAYASHISHINYA}____AritsuneTsuji{TSUJIARITSUNE}|TaroKamemura{KAMEMURATARO}|AyakaIto{ITOAYAKA}|RikuoHase{HASERIKUO}|TomohiroSuzuki{SUZUKITOMOHIRO}|YusukeYano{YANOYUSUKE}|HirotakaTsuno{TSUNOHIROTAKA}|ToshihiroMastui{MASTUITOSHIHIRO}|RyuWatanebe{WATANEBERYU}|TadashiOkano{OKANOTADASHI}|AkiraOnishi{ONISHIAKIRA}|KosakuMurakami{MURAKAMIKOSAKU}|KosukeEbina{EBINAKOSUKE}|HirotakaYamada{YAMADAHIROTAKA}|MaiYamashita{YAMASHITAMAI}|TohruTakeuchi{TAKEUCHITOHRU}|AyakaYoshikawa{YOSHIKAWAAYAKA}|YonsuSon{SONYONSU}|HidehikoMakino{MAKINOHIDEHIKO}|YujiNozaki{NOZAKIYUJI}|TetsuItami{ITAMITETSU}|WataruYamamoto{YAMAMOTOWATARU}|YuyaYano{YANOYUYA}|TasukuTogashi{TOGASHITASUKU}|RyuheiIshihara{ISHIHARARYUHEI}|MasaoKatsushima{KATSUSHIMAMASAO}|KazuoFukumoto{FUKUMOTOKAZUO}|ShinsukeYamada{YAMADASHINSUKE}|MotomuHashimoto{HASHIMOTOMOTOMU}|MasahiroHanabayashi{HANABAYASHIMASAHIRO}|YutakaYokota{YOKOTAYUTAKA}|HideNagaba{NAGABAHIDE}|JunichiKondo{KONDOJUNICHI}|EisukeOgawa{OGAWAEISUKE}|KunihiroYamaoka{YAMAOKAKUNIHIRO}|ShigeruIwata{IWATASHIGERU}|RyoMatsumiya{MATSUMIYARYO}|TakashiKato{KATOTAKASHI}|KodaiUeno{UENOKODAI}|TaroNishikawa{NISHIKAWATARO}|TakeruSonoda{SONODATAKERU}|TakaoFujii{FUJIITAKAO}|HirotakaYamazawa{YAMAZAWAHIROTAKA}|KaoriIshimura{ISHIMURAKAORI}|ChisatoAshida{ASHIDACHISATO}|DaisukeTomita{TOMITADAISUKE}|ToshihikoShiga{SHIGATOSHIHIKO}|KazuyaKishimoto{KISHIMOTOKAZUYA}|KojiKinoshita{KINOSHITAKOJI}|IkuShirasugi{SHIRASUGIIKU}|NaofumiYoshida{YOSHIDANAOFUMI}|RyuWatanabe{WATANABERYU}|YasutakaOkita{OKITAYASUTAKA}____Workshop 16DMARDs・NSAIDs・others for RA treatment 2____The change of treatment and effectiveness of Gold Sodium Thiomalate (GST) over 20 years: considerations for supply instability|Evaluation of Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy for Biologic Agents and JAK Inhibitors in Patients with Rheumatoid Arthritis: The ANSWER Cohort|Investigation of backgrounds of rheumatoid patients initiated on Tacrolimus in our hospital|Challenges of Hospital-Clinic Cooperation at Our Hospital Based on a Post-Hoc Analysis of Glucocorticoid Use in Rheumatoid Arthritis Treatment|The efficacy and safety of switching from oral MTX to subcutaneous injection in patients with rheumatoid arthritis|Investigation of Initial Treatment Strategies in MTX-Ineligible Patients in the ANSWER Cohort

W16

Workshop 16
DMARDs・NSAIDs・others for RA treatment 2

Chair：Shinya Hayashi

DaisukeKobayashi{KOBAYASHIDAISUKE}|MasahiroKonishi{KONISHIMASAHIRO}|TakayoshiFujibayashi{FUJIBAYASHITAKAYOSHI}|KosukeEbina{EBINAKOSUKE}|NanaUematsu{UEMATSUNANA}|KunihiroYamaoka{YAMAOKAKUNIHIRO}____EiichiTanaka{TANAKAEIICHI}____YuutoTanno{TANNOYUUTO}|NaokiKondo{KONDONAOKI}|SatoshiIto{ITOSATOSHI}|YokoWada{WADAYOKO}|ErikoHasegawa{HASEGAWAERIKO}|AyakoWakamatsu{WAKAMATSUAYAKO}|YoichiKurosawa{KUROSAWAYOICHI}|SyunsukeSakai{SAKAISYUNSUKE}|YukikoNozawa{NOZAWAYUKIKO}|HiroeSato{SATOHIROE}|YusukeTakahashi{TAKAHASHIYUSUKE}|KahoSato{SATOKAHO}|TomoyaWatarai{WATARAITOMOYA}|TakeshiKuroda{KURODATAKESHI}|IchiroMizushima{MIZUSHIMAICHIRO}|HajimeSanada{SANADAHAJIME}|SatoshiNakazaki{NAKAZAKISATOSHI}|TakashiMurayama{MURAYAMATAKASHI}|IsaoMatsushita{MATSUSHITAISAO}|ToshikiKido{KIDOTOSHIKI}|HiroshiFujinaga{FUJINAGAHIROSHI}|RenaTsuda{TSUDARENA}|HirakuMotomura{MOTOMURAHIRAKU}|TakahiroYamano{YAMANOTAKAHIRO}|YasuoKatsuki{KATSUKIYASUO}|TetsuoWatanabe{WATANABETETSUO}|MegumiOshima{OSHIMAMEGUMI}|ShioriNakagawa{NAKAGAWASHIORI}|RyoNishioka{NISHIOKARYO}|KiyoakiIto{ITOKIYOAKI}|ShinjiKitajima{KITAJIMASHINJI}|NorihikoSakai{SAKAINORIHIKO}|MihoShimizu{SHIMIZUMIHO}|MitsuhiroKawano{KAWANOMITSUHIRO}|TakashiWada{WADATAKASHI}|YasunoriIwata{IWATAYASUNORI}|KazunoriYamada{YAMADAKAZUNORI}|YasuhideKanayama{KANAYAMAYASUHIDE}|YoutaGoto{GOTOYOUTA}|ShunpeiMiyake{MIYAKESHUNPEI}|ToshiakiOkura{OKURATOSHIAKI}|MasashiKawasaki{KAWASAKIMASASHI}|YujiHirano{HIRANOYUJI}|ShujiAsai{ASAISHUJI}|ToshihisaKojima{KOJIMATOSHIHISA}|MasatoshiKamori{KAMORIMASATOSHI}|NobunoriTakahashi{TAKAHASHINOBUNORI}|YukiEtani{ETANIYUKI}|TakaakiNoguchi{NOGUCHITAKAAKI}|YasutakaOkita{OKITAYASUTAKA}|KoheiTsujimoto{TSUJIMOTOKOHEI}|YuichiMaeda{MAEDAYUICHI}|KoichiMurata{MURATAKOICHI}|TakayukiFujii{FUJIITAKAYUKI}|MotomuHashimoto{HASHIMOTOMOTOMU}|TadashiOkano{OKANOTADASHI}|HirotakaYamada{YAMADAHIROTAKA}|YoUeda{UEDAYO}|TohruTakeuchi{TAKEUCHITOHRU}|HideyukiShiba{SHIBAHIDEYUKI}|YonsuSon{SONYONSU}|HidehikoMakino{MAKINOHIDEHIKO}|YujiNozaki{NOZAKIYUJI}|DaisukeTomita{TOMITADAISUKE}|WataruYamamoto{YAMAMOTOWATARU}|AtsushiKumanogoh{KUMANOGOHATSUSHI}|SeijiOkada{OKADASEIJI}|HirotoTsuboi{TSUBOIHIROTO}|AkiyoshiRai{RAIAKIYOSHI}|KotomiMurata{MURATAKOTOMI}|MoeYamada{YAMADAMOE}|MamiYoshida{YOSHIDAMAMI}|FumiyukiShibasaki{SHIBASAKIFUMIYUKI}|TomonoriHishinuma{HISHINUMATOMONORI}|FuminaKawashima{KAWASHIMAFUMINA}|ToshikiSugita{SUGITATOSHIKI}|AyakoOhyama{OHYAMAAYAKO}|SaoriAbe{ABESAORI}|AyakoKitada{KITADAAYAKO}|HarukaMiki{MIKIHARUKA}|HiromitsuAsashima{ASASHIMAHIROMITSU}|YuyaKondo{KONDOYUYA}|IsaoMatsumoto{MATSUMOTOISAO}|KevinWinthrop{WINTHROPKEVIN}|SaraK.Penn{PENNSARAK.}|JustinKlaff{KLAFFJUSTIN}|YanxiLiu{LIUYANXI}|ConradoGarcía{GARCÍACONRADO}|EduardoMysler{MYSLEREDUARDO}|AlvinWells{WELLSALVIN}|XianweiBu{BUXIANWEI}|NasserNasser{NASSERNASSER}|MichaelChen{CHENMICHAEL}|AnthonyL.Cunningham{CUNNINGHAMANTHONYL.}____Workshop 17Outcome measures and prediction for RA treatment: b/tsDMARDs____Analysis of factors associated with Upadacitinib-effective patients with Japanese rheumatoid arthritis: A Multi-Center Observational Study in Niigata Prefecture (SELECT-NIIGATA study)|Analysis of efficacy, safety and related factors in 450 cases of rheumatoid arthritis treated with JAK inhibitors - Study in the rheumatoid arthritis cohort FIT-RA -|Treatment response in patients with rheumatoid arthritis treated with certolizumab pegol based on rheumatoid factor levels|Development of Artificial Intelligence (AI) for Predicting Treatment Outcomes of RA with Molecular Targeted Therapy: The ANSWER Cohort Study|Affects of Janus kinase inhibitor (JAKi) and Abatacept (ABT) on lung involvements in rheumatoid arthritis (RA)|Immunogenicity of an Adjuvant Recombinant Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Upadacitinib: 60-Week Results From a Randomized Substudy

W17

Workshop 17
Outcome measures and prediction for RA treatment: b/tsDMARDs

Chair：Eiichi Tanaka

OsamuNishiyama{NISHIYAMAOSAMU}____MasatoOkada{OKADAMASATO}________Luncheon Seminar 9Treatment Strategies for CTD-PAH Considering Concomitant Respiratory Diseases: Including experiences with Selexipag____Treatment Strategies for CTD-PAH Considering Concomitant Respiratory Diseases: Including experiences with Selexipag

LS9

Luncheon Seminar 9
Treatment Strategies for CTD-PAH Considering Concomitant Respiratory Diseases: Including experiences with Selexipag

【Sponsored by NIPPON SHINYAKU CO.,LTD. / Janssen Pharmaceutical K.K.】

Chair：Masato Okada

Speaker：Osamu Nishiyama

TomohiroKoga{KOGATOMOHIRO}|TakeshiUrano{URANOTAKESHI}|ShoichiFukui{FUKUISHOICHI}|KanaHigashitani{HIGASHITANIKANA}|TatsumaBan{BANTATSUMA}|NaotoYokogawa{YOKOGAWANAOTO}____TomohiroKoga{KOGATOMOHIRO}|YoheiKirino{KIRINOYOHEI}____MasatakaUmeda{UMEDAMASATAKA}|AtsushiKawakami{KAWAKAMIATSUSHI}|RemiSumiyoshi{SUMIYOSHIREMI}|TomohiroKoga{KOGATOMOHIRO}|YoheiKirino{KIRINOYOHEI}|SouichirouAdachi{ADACHISOUICHIROU}|HideakiNakajima{NAKAJIMAHIDEAKI}____Symposium 6How to develop/manage molecularly targeted drugs in intractable RMDs____Development of a Japanese Familial Mediterranean Fever Model Mouse and Novel Therapeutic Strategies for Drug Discovery|Development of a new treatment targeting the active inflammatory cytokine IL-18|Development of new treatments for idiopathic multicentric Castleman disease|Identification of Therapeutic Targets in VEXAS Syndrome Through Multi-Omics Analysis Based on Clinical Data|Pathophysiology and therapeutic development for systemic lupus erythematosus focusing on transcription factor IRF5|Prevention of recurrence of congenital heart block in pregnancies of anti-SS-A-positive women using hydroxychloroquine (AMED-BIRTHDAY)

S6

Symposium 6
How to develop/manage molecularly targeted drugs in intractable RMDs

Chair：Tomohiro Koga, Chair：Yohei Kirino

Speaker：Tomohiro Koga

Speaker：Takeshi Urano

Speaker：Shoichi Fukui

Speaker：Kana Higashitani

Speaker：Tatsuma Ban

Speaker：Naoto Yokogawa

KouChiba{CHIBAKOU}____MasaruIshii{ISHIIMASARU}________Evening Seminar 6Treatment Strategies for Osteoporosis: The Role of Abaloparatide____Treatment Strategies for Osteoporosis: The Role of Abaloparatide

ES6

Evening Seminar 6
Treatment Strategies for Osteoporosis: The Role of Abaloparatide

【Sponsored by Teijin Healthcare Limited】

Chair：Masaru Ishii

Speaker：Kou Chiba

WataruFujii{FUJIIWATARU}|TakuroNii{NIITAKURO}|YasuhikoYoshinaga{YOSHINAGAYASUHIKO}|AkiraNishigaichi{NISHIGAICHIAKIRA}|HayateUmemoto{UMEMOTOHAYATE}|TsuyoshiNishiume{NISHIUMETSUYOSHI}____YoshinoriKomagata{KOMAGATAYOSHINORI}|JunSaegusa{SAEGUSAJUN}____AkiSakashita{SAKASHITAAKI}|AikoHirano{HIRANOAIKO}|TakashiKida{KIDATAKASHI}|TakahiroSeno{SENOTAKAHIRO}|MasatakaKohno{KOHNOMASATAKA}|YutakaKawahito{KAWAHITOYUTAKA}|YukiHara{HARAYUKI}|AkiraMiyama{MIYAMAAKIRA}|KoichiroTakahi{TAKAHIKOICHIRO}|HiroshiKida{KIDAHIROSHI}|KeijiOhashi{OHASHIKEIJI}|TetsushiAita{AITATETSUSHI}|SusumuNishiyama{NISHIYAMASUSUMU}|ToshihiroMatsui{MATSUITOSHIHIRO}|ShigetoTohma{TOHMASHIGETO}|ErikaIguchi{IGUCHIERIKA}|YanakaweeSiripongvutikorn{SIRIPONGVUTIKORNYANAKAWEE}|DongseopKim{KIMDONGSEOP}|KurumiYamamoto{YAMAMOTOKURUMI}|MaikoYoshimura{YOSHIMURAMAIKO}|AkihikoNakabayashi{NAKABAYASHIAKIHIKO}|HyoutaTakamatsu{TAKAMATSUHYOUTA}|ShiroOhshima{OHSHIMASHIRO}|ReikaUchida{UCHIDAREIKA}|MakotoSoejima{SOEJIMAMAKOTO}____Workshop 18Rheumatic diseases and mycobacterial/bacterial infections____The impact of pulmonary non-tuberculous mycobacteria on RA treatment|Rheumatoid arthritis as an independent adverse prognostic factor in pulmonary nontuberculous mycobacterial disease: a single-center retrospective study|A reconfirmation of the 20-year trend in standardized incidence rates (SIRs) of tuberculosis (TB) in rheumatoid arthritis (RA) patients based on National Database of Rheumatic Diseases in Japan (NinJa) and the analysis of the clinical characteristics of 84 newly developed TB cases|Efficacy of abatacept for rheumatoid arthritis complicated with nontuberoculous mycobacterium|Nontuberculous mycobacterial arthritis as an extrapulmonary lesion in a patient with rheumatoid arthritis|Comparison of glucocorticoid (GC) therapy and JAK inhibitor therapy in patients with PMR (PolyMyalgia Rheumatica)

W18

Workshop 18
Rheumatic diseases and mycobacterial/bacterial infections

Chair：Yoshinori Komagata, Chair：Jun Saegusa

TakuyaKotani{KOTANITAKUYA}|TomoyaNishida{NISHIDATOMOYA}|KotaroKitade{KITADEKOTARO}|HirofumiMiyake{MIYAKEHIROFUMI}|ShinjiSato{SATOSHINJI}|TaroUkichi{UKICHITARO}____RanNakashima{NAKASHIMARAN}____ShogoMatsuda{MATSUDASHOGO}|AyaSakamoto{SAKAMOTOAYA}|YoshihiroSho{SHOYOSHIHIRO}|TakeshiShoda{SHODATAKESHI}|TohruTakeuchi{TAKEUCHITOHRU}|MasahiroAyano{AYANOMASAHIRO}|ShoFujimoto{FUJIMOTOSHO}|NaoyaNishimura{NISHIMURANAOYA}|AyakoKuwahara{KUWAHARAAYAKO}|YasutakaKimoto{KIMOTOYASUTAKA}|GoroDoi{DOIGORO}|DaisukeOryoji{ORYOJIDAISUKE}|HirokiMitoma{MITOMAHIROKI}|NaoyasuUeda{UEDANAOYASU}|TomoharuSaito{SAITOTOMOHARU}|TakuyaSawabe{SAWABETAKUYA}|YasushiInoue{INOUEYASUSHI}|FumiakiSagawa{SAGAWAFUMIAKI}|SeijiYoshizawa{YOSHIZAWASEIJI}|YoshifumiTada{TADAYOSHIFUMI}|HiroakiNiiro{NIIROHIROAKI}|NobuyukiOno{ONONOBUYUKI}|AtsushiOnoe{ONOEATSUSHI}|TakuyaOkada{OKADATAKUYA}|YusukeTarutani{TARUTANIYUSUKE}|MakoYamamotoShimomura{YAMAMOTOSHIMOMURAMAKO}|MoemiYabe{YABEMOEMI}|KentaMisaki{MISAKIKENTA}|YasuhikoImaizumi{IMAIZUMIYASUHIKO}|RanNakashima{NAKASHIMARAN}|HideakiTsuji{TSUJIHIDEAKI}|TsuneoSasai{SASAITSUNEO}|YasuhiroNohda{NOHDAYASUHIRO}|TsuneyasuYoshida{YOSHIDATSUNEYASU}|YoichiNakayama{NAKAYAMAYOICHI}|YutoNakakubo{NAKAKUBOYUTO}|AtsubumiOgawa{OGAWAATSUBUMI}|KazumaYoshida{YOSHIDAKAZUMA}|KeisukeHirobe{HIROBEKEISUKE}|YukiAitani{AITANIYUKI}|YudaiKoshida{KOSHIDAYUDAI}|ChifumiAkiyama{AKIYAMACHIFUMI}|MahiroYamamoto{YAMAMOTOMAHIRO}|KatsumasaOe{OEKATSUMASA}|TakayasuSuzuka{SUZUKATAKAYASU}|TakuyaKotani{KOTANITAKUYA}|TakahisaGono{GONOTAKAHISA}|AkiraYoshida{YOSHIDAAKIRA}|TakeshiJohkoh{JOHKOHTAKESHI}|TakanoriIto{ITOTAKANORI}|AtsushiKawakami{KAWAKAMIATSUSHI}|YasushiKawaguchi{KAWAGUCHIYASUSHI}|TomoakiHoshino{HOSHINOTOMOAKI}|MasatakaKuwana{KUWANAMASATAKA}|KenYoshida{YOSHIDAKEN}|KentaroNoda{NODAKENTARO}|HaruyasuIto{ITOHARUYASU}|KazuhiroOtani{OTANIKAZUHIRO}|YohsukeOto{OTOYOHSUKE}|TakayukiMatsushita{MATSUSHITATAKAYUKI}|MasayoriMoriyama{MORIYAMAMASAYORI}|DaitaroKurosaka{KUROSAKADAITARO}____Workshop 19Polymyositis and dermatomyositis: pathogenesis and imaging: interstitial lung diseases____Analysis of chest HRCT findings defined by progressive pulmonary fibrosis in idiopathic inflammatory myopathy-related interstitial lung disease|Predictors of good Long-Term Prognosis in Patients with ILD-associated anti-MDA-5 antibody-positive dermatomyositis|The characteristics and outcome of anti-MDA5 antibody-positive dermatomyositis cases during 7 years in our single center|Validation of the MCK model for predicting outcomes in inflammatory myopathy associated interstitial lung disease: A multicentre MYKO cohort study|Potential for a novel disease classification in myositis-associated interstitial lung disease: Analysis in the JAMI-2R cohort|Predictive Factors for the Efficacy of High-Dose Intravenous Immunoglobulin Therapy: A Retrospective Analysis of Dermatomyositis with Rapidly Progressive Interstitial Lung Disease

W19

Workshop 19
Polymyositis and dermatomyositis: pathogenesis and imaging: interstitial lung diseases

Chair：Ran Nakashima

ShingoNakayamada{NAKAYAMADASHINGO}____KeiichiroNishida{NISHIDAKEIICHIRO}________Luncheon Seminar 10Challenges in Rheumatoid Arthritis Treatment and Expectations for JAK Inhibitors____Challenges in Rheumatoid Arthritis Treatment and Expectations for JAK Inhibitors

LS10

Luncheon Seminar 10
Challenges in Rheumatoid Arthritis Treatment and Expectations for JAK Inhibitors

【Sponsored by Astellas Pharma Inc.】

Chair：Keiichiro Nishida

Speaker：Shingo Nakayamada

ShintaroTsumura{TSUMURASHINTARO}|NaokoIto{ITONAOKO}|AyanaOkazaki{OKAZAKIAYANA}|TakuyaKotani{KOTANITAKUYA}|MikiNakano{NAKANOMIKI}|SusumuTsunoda{TSUNODASUSUMU}____TakuyaKotani{KOTANITAKUYA}|TakashiYamane{YAMANETAKASHI}____NoriyukiNamura{NAMURANORIYUKI}|YoshihiroSho{SHOYOSHIHIRO}|KazuyaKamada{KAMADAKAZUYA}|SatoshiKashiwagi{KASHIWAGISATOSHI}|TakafumiHagiwara{HAGIWARATAKAFUMI}|ShogoMatsuda{MATSUDASHOGO}|AyanaOkazaki{OKAZAKIAYANA}|YuichiMasuda{MASUDAYUICHI}|TakuyaKotani{KOTANITAKUYA}|TomokiTaniguchi{TANIGUCHITOMOKI}|MikihitoShoji{SHOJIMIKIHITO}|AtsushiManabe{MANABEATSUSHI}|KeiichiroKadoba{KADOBAKEIICHIRO}|MuneyukiHatta{HATTAMUNEYUKI}|MayuShiomi{SHIOMIMAYU}|RyuWatanabe{WATANABERYU}|HirofumiMiyake{MIYAKEHIROFUMI}|WataruYamamoto{YAMAMOTOWATARU}|MotomuHashimoto{HASHIMOTOMOTOMU}|YouheiFujiki{FUJIKIYOUHEI}|TsuneyasuYoshida{YOSHIDATSUNEYASU}|NaokoIto{ITONAOKO}|TohruTakeuchi{TAKEUCHITOHRU}|RyosukeHiwa{HIWARYOSUKE}|NobuyukiOno{ONONOBUYUKI}|YasushiInoue{INOUEYASUSHI}|TatsuyaKai{KAITATSUYA}|SotaKamikawa{KAMIKAWASOTA}|AtsushiTanaka{TANAKAATSUSHI}|NaoyasuUeda{UEDANAOYASU}|TomoyaMiyamura{MIYAMURATOMOYA}|HisakoInoue{INOUEHISAKO}|AyumiUchino{UCHINOAYUMI}|SeijiYoshizawa{YOSHIZAWASEIJI}|TakuyaSawabe{SAWABETAKUYA}|Shun-IchiroOta{OTASHUN-ICHIRO}|YutakaChifu{CHIFUYUTAKA}|KojiMishima{MISHIMAKOJI}|KatsuhisaMiyake{MIYAKEKATSUHISA}|YasutakaKimoto{KIMOTOYASUTAKA}|HirokiMitoma{MITOMAHIROKI}|TakahikoHoriuchi{HORIUCHITAKAHIKO}|YoshifumiTada{TADAYOSHIFUMI}|HiroakiNiiro{NIIROHIROAKI}|HisashiSugimoto{SUGIMOTOHISASHI}|YuusukeYoshimura{YOSHIMURAYUUSUKE}|ShigekazuKurihara{KURIHARASHIGEKAZU}|YuukiOba{OBAYUUKI}|MasayukiYamanouchi{YAMANOUCHIMASAYUKI}|TatuyaSuwabe{SUWABETATUYA}|YoshihumiUbara{UBARAYOSHIHUMI}|NaokiSawa{SAWANAOKI}____Workshop 20ANCA-associate vaslulitis: disease course and outcome____Risk Factors for Mortality in patients with ANCA-associated Vasculitis|Predictive factors for home discharge in microscopic polyangiitis: A multicenter REVEAL cohort study|A study of the relapse and prognosis in granulomatosis with polyangiitis (GPA) - The REVEAL cohort study-|Risk factors for severe respiratory distress in patients with AAV complicated by diffuse alveolar hemorrhage: the REVEAL cohort study|Clinical characteristics and prognostic factors in patients with ANCA-associated vasculitis with diffuse alveolar hemorrhage|Comparative Study of ANCA-Associated Vasculitis in Patients With and Without Rheumatoid Arthritis: Analysis of Clinical Manifestations and Renal Outcomes

W20

Workshop 20
ANCA-associate vaslulitis: disease course and outcome

Chair：Takuya Kotani, Chair：Takashi Yamane

KeikoYoshimoto{YOSHIMOTOKEIKO}|HirofumiToko{TOKOHIROFUMI}|KumikoAkiya{AKIYAKUMIKO}|KentaroNoda{NODAKENTARO}|TakeshiKashio{KASHIOTAKESHI}____MinakoTomiita{TOMIITAMINAKO}|SusumuNishiyama{NISHIYAMASUSUMU}____HiroyukiFukui{FUKUIHIROYUKI}|KotaroMatsumoto{MATSUMOTOKOTARO}|MasaruTakeshita{TAKESHITAMASARU}|YukoKaneko{KANEKOYUKO}|KatsuyaSuzuki{SUZUKIKATSUYA}|ChihiroTakahashi{TAKAHASHICHIHIRO}|TsutomuTakeuchi{TAKEUCHITSUTOMU}|HirotoTsuboi{TSUBOIHIROTO}|HiroyukiTakahashi{TAKAHASHIHIROYUKI}|FumikaHonda{HONDAFUMIKA}|SaoriAbe{ABESAORI}|AyakoOhyama{OHYAMAAYAKO}|AyakoKitada{KITADAAYAKO}|HarukaMiki{MIKIHARUKA}|HiromitsuAsashima{ASASHIMAHIROMITSU}|YuyaKondo{KONDOYUYA}|TakayukiSumida{SUMIDATAKAYUKI}|IsaoMatsumoto{MATSUMOTOISAO}|MasashiUchikawa{UCHIKAWAMASASHI}|KiichiSugito{SUGITOKIICHI}|ShinyaAsatani{ASATANISHINYA}|MasahiroNishihara{NISHIHARAMASAHIRO}|YousukeNagasawa{NAGASAWAYOUSUKE}|HirotakeInomata{INOMATAHIROTAKE}|MihoOshima{OSHIMAMIHO}|NoboruKitamura{KITAMURANOBORU}|MasakoYamada{YAMADAMASAKO}|HidekiNakamura{NAKAMURAHIDEKI}|HaruyasuIto{ITOHARUYASU}|TaroUkichi{UKICHITARO}|KenYoshida{YOSHIDAKEN}|DaitaroKurosaka{KUROSAKADAITARO}|HirotakaYamamoto{YAMAMOTOHIROTAKA}|SatoshiInotani{INOTANISATOSHI}|YoshinoriTaniguchi{TANIGUCHIYOSHINORI}|TaroHorino{HORINOTARO}____Workshop 21Pathogenesis of Sjögren's syndrome____Elevated expression of a BAFF receptor, BR3, in peripheral monocytes and serum level of soluble BR3 are correlated with clinical features of Sjögren's syndrome|The involvement of TLR4 signaling pathways in the elevation of BAFF receptor, BR3, expression in peripheral monocytes of patients with Sjögren's syndrome|Association between CD8 positive regulatory T cells (CD8+Treg) and clinical features in patients with primary Sjögren's syndrome (pSS), and inhibition of the pathogenesis via the induction of CD8+Treg differentiation|Analysis of intestinal flora in patients with Sjögren's syndrome|Central sensitivity syndrome in patients with Sjögren syndrome|A case of tubulointerstitial nephritis and Fanconi syndrome in a patient with primary Sjögren's syndrome accompanied by anti-mitochondrial antibodies

W21

Workshop 21
Pathogenesis of Sjögren's syndrome

Chair：Minako Tomiita, Chair：Susumu Nishiyama

KosukeEbina{EBINAKOSUKE}____SakaeTanaka{TANAKASAKAE}____YukiEtani{ETANIYUKI}|TakaakiNoguchi{NOGUCHITAKAAKI}|SeijiOkada{OKADASEIJI}____Educational Lecture 5Abnormal Bone Metabolism and Its Management in Rheumatic Diseases: Essential Knowledge for Rheumatologists____Abnormal Bone Metabolism and Its Management in Rheumatic Diseases: Essential Knowledge for Rheumatologists

EL5

Educational Lecture 5
Abnormal Bone Metabolism and Its Management in Rheumatic Diseases: Essential Knowledge for Rheumatologists

Chair：Sakae Tanaka

Lecturer：Kosuke Ebina

YuMunakata{MUNAKATAYU}____ToshihideMimura{MIMURATOSHIHIDE}________Educational Lecture 6____－

EL6

Educational Lecture 6

Chair：Toshihide Mimura

Lecturer：Yu Munakata

YujiNozaki{NOZAKIYUJI}____AkioMorinobu{MORINOBUAKIO}________Luncheon Seminar 11Optimal Treatment Strategies in Rheumatoid Arthritis with Poor Prognostic Factors for Joint Destruction: Key Considerations from the Perspectives of Rheumatology and Nephrology Specialists____Optimal Treatment Strategies in Rheumatoid Arthritis with Poor Prognostic Factors for Joint Destruction: Key Considerations from the Perspectives of Rheumatology and Nephrology Specialists

LS11

Luncheon Seminar 11
Optimal Treatment Strategies in Rheumatoid Arthritis with Poor Prognostic Factors for Joint Destruction: Key Considerations from the Perspectives of Rheumatology and Nephrology Specialists

【Sponsored by Eli Lilly Japan K.K.】

Chair：Akio Morinobu

Speaker：Yuji Nozaki

MasaakiMori{MORIMASAAKI}|MasakiShimizu{SHIMIZUMASAKI}____NamiOkamoto{OKAMOTONAMI}________Educational Lecture 7Overview of the clinical practice guideline for juvenile idiopathic arthritis / Development of clinical guideline for the management of pediatric onset systemic lupus erythematosus in Japan____Overview of the clinical practice guideline for juvenile idiopathic arthritis|Development of clinical guideline for the management of pediatric onset systemic lupus erythematosus in Japan

EL7

Educational Lecture 7
Overview of the clinical practice guideline for juvenile idiopathic arthritis / Development of clinical guideline for the management of pediatric onset systemic lupus erythematosus in Japan

Chair：Nami Okamoto

Lecturer：Masaaki Mori

Lecturer：Masaki Shimizu

KosakuMurakami{MURAKAMIKOSAKU}____ToshihiroNanki{NANKITOSHIHIRO}________Educational Lecture 8Immune-Related Adverse Events: The Role of the Rheumatologist____Immune-Related Adverse Events: The Role of the Rheumatologist

EL8

Educational Lecture 8
Immune-Related Adverse Events: The Role of the Rheumatologist

Chair：Toshihiro Nanki

Lecturer：Kosaku Murakami

SusumuNakae{NAKAESUSUMU}|KeiIkeda{IKEDAKEI}____MasatoOkada{OKADAMASATO}________Evening Seminar 7Advances in Understanding Inflammation Control in Spondyloarthritis____Molecular mechanism for oathogenesis of spondyloarthritis: Bridging the basic and clinical researches|Treatment strategy of psoriatic arthritis and axial spondylitis based on pathophysiology

ES7

Evening Seminar 7
Advances in Understanding Inflammation Control in Spondyloarthritis

【Sponsored by UCB Japan Co. Ltd.】

Chair：Masato Okada

Speaker：Susumu Nakae

Speaker：Kei Ikeda

MasatoshiKawataka{KAWATAKAMASATOSHI}|CristinaMacía-Villa{MACÍA-VILLACRISTINA}|TaigaKuga{KUGATAIGA}|Yen-AnChang{CHANGYEN-AN}|Ki-JeongPark{PARKKI-JEONG}____SaoriAbe{ABESAORI}|TsuneyasuYoshida{YOSHIDATSUNEYASU}____SatoshiYamaguchi{YAMAGUCHISATOSHI}|IkumaOkada{OKADAIKUMA}|NaonoriSugishita{SUGISHITANAONORI}|MihoYamazaki{YAMAZAKIMIHO}|RyokoAsano{ASANORYOKO}|ToshikiKido{KIDOTOSHIKI}|HiroyukiHounoki{HOUNOKIHIROYUKI}|MasaruKato{KATOMASARU}|KurisuTada{TADAKURISU}|KenYamaji{YAMAJIKEN}|NaotoTamura{TAMURANAOTO}|Ming-HanChen{CHENMING-HAN}____Symposium 7 (J-STAR Session)Comprehensive approach to Difficult to treat PsA/axSpA: from bench to clinical practice____A case of D2TPsA mimicking rheumatoid arthritis and requiring frequent treatment switching|Difficult to treat Psoriatic Arthritis|A Case of Axial Spondyloarthritis with Response to NSAIDs but Radiographic Progression: Challenges in Monitoring and Treatment Approaches|Clinical Characteristics and Predictors of Difficult-to-Manage Axial Spondyloarthritis: Insights from a Single-Center Retrospective Study|A Comprehensive overview of basic research in Spondyloarthritis

S7

Symposium 7 (J-STAR Session)
Comprehensive approach to Difficult to treat PsA/axSpA: from bench to clinical practice

Chair：Saori Abe, Chair：Tsuneyasu Yoshida

Speaker：Masatoshi Kawataka

Speaker：Cristina Macía-Villa

Speaker：Taiga Kuga

Speaker：Yen-An Chang

Speaker：Ki-Jeong Park

HidekataYasuoka{YASUOKAHIDEKATA}____MasatakaKuwana{KUWANAMASATAKA}________Luncheon Seminar 12For the standardization of the treatment for the interstitial lung disease (ILD) in Systemic Sclerosis (SSc)____For the standardization of the treatment for the interstitial lung disease (ILD) in Systemic Sclerosis (SSc)

LS12

Luncheon Seminar 12
For the standardization of the treatment for the interstitial lung disease (ILD) in Systemic Sclerosis (SSc)

【Sponsored by Chugai Pharmaceutical Co., Ltd.】

Chair：Masataka Kuwana

Speaker：Hidekata Yasuoka

BlagojeSoskic{SOSKICBLAGOJE}|ChunJimmieYe{YECHUNJIMMIE}|YukinoriOkada{OKADAYUKINORI}|ShyamPrabhakar{PRABHAKARSHYAM}|MasayukiNishide{NISHIDEMASAYUKI}____YukinoriOkada{OKADAYUKINORI}|ShyamPrabhakar{PRABHAKARSHYAM}____PietroDemela{DEMELAPIETRO}|LauraEsposito{ESPOSITOLAURA}|PietroMarchesan{MARCHESANPIETRO}|GracieGordon{GORDONGRACIE}|PoojaKathail{KATHAILPOOJA}|TaiboLi{LITAIBO}|YangSun{SUNYANG}|HananeTouil{TOUILHANANE}|LindseyLiang{LIANGLINDSEY}|MelissaGearing{GEARINGMELISSA}|AlyssaWard{WARDALYSSA}|DivyaKushnoor{KUSHNOORDIVYA}|SabaShaikh{SHAIKHSABA}|AnniePoon{POONANNIE}|CatChu{CHUCAT}|JoelBador{BADORJOEL}|AntonOgorodnikov{OGORODNIKOVANTON}|RaymundBueno{BUENORAYMUND}|MarcusAlvarez{ALVAREZMARCUS}|MincheolKim{KIMMINCHEOL}|DavidLee{LEEDAVID}|TaraTaeed{TAEEDTARA}|MariaCalvo{CALVOMARIA}|CollinOcampo{OCAMPOCOLLIN}|KahoOnomichi{ONOMICHIKAHO}|JessicaTsui{TSUIJESSICA}|MatthewSpitzer{SPITZERMATTHEW}|StephenSanders{SANDERSSTEPHEN}|NoahZaitlen{ZAITLENNOAH}|AlexisCombes{COMBESALEXIS}|AlexisBattle{BATTLEALEXIS}|PhilDejager{DEJAGERPHIL}____Symposium 8Profiling human disease immunology by single cell multi-omics analyses____Transcriptional control of human B cell activation and antibody production|Single cell multiomics across diverse humanpopulations reveals novel genetic determinants andmechanisms of immune-related complex diseases|Projecting human disease omics into single cell resolution|Single cell analysis reveals Asian diversity and immune disease markers|Single-cell multi-omics analysis in rheumatic and allergic diseases

S8

Symposium 8
Profiling human disease immunology by single cell multi-omics analyses

Chair：Yukinori Okada, Chair：Shyam Prabhakar

Speaker：Blagoje Soskic

Speaker：Chun Jimmie Ye

Speaker：Yukinori Okada

Speaker：Shyam Prabhakar

Speaker：Masayuki Nishide

AkikazuMurakami{MURAKAMIAKIKAZU}|KosukeEbina{EBINAKOSUKE}|TsutomuTakeuchi{TAKEUCHITSUTOMU}____AtsushiKawakami{KAWAKAMIATSUSHI}________Evening Seminar 8Considering rheumatology treatment using next-generation antibodies____The Future of VHH Antibodies: Insights from Existing Antibody Therapeutics|The Potential of Next-Generation Small-Molecule Antibody Ozoralizumab in Revolutionizing RA Treatment|Latest Findings regarding a Novel TNF Inhibitor, Ozoralizumab

ES8

Evening Seminar 8
Considering rheumatology treatment using next-generation antibodies

【Sponsored by Taisho Pharmaceutical Co., Ltd】

Chair：Atsushi Kawakami

Speaker：Akikazu Murakami

Speaker：Kosuke Ebina

Speaker：Tsutomu Takeuchi

IkuoTakazawa{TAKAZAWAIKUO}|MichihiroKono{KONOMICHIHIRO}|YongmeiY.Yu{YUYONGMEIY.}|ShoIshigaki{ISHIGAKISHO}|－____TadashiHosoya{HOSOYATADASHI}____SotaroNakajima{NAKAJIMASOTARO}|KazuoOkamoto{OKAMOTOKAZUO}|RisaYoshihara{YOSHIHARARISA}|TomohisaOkamura{OKAMURATOMOHISA}|HiroshiTakayanagi{TAKAYANAGIHIROSHI}|HarukaTsuchiya{TSUCHIYAHARUKA}|KeishiFujio{FUJIOKEISHI}|HiroakiHatano{HATANOHIROAKI}|TakahiroNishino{NISHINOTAKAHIRO}|HarukaTakahashi{TAKAHASHIHARUKA}|MasahiroNakano{NAKANOMASAHIRO}|BunkiNatsumoto{NATSUMOTOBUNKI}|KazuyoshiIshigaki{ISHIGAKIKAZUYOSHI}|HongweiH.Lei{LEIHONGWEIH.}|YangLi{LIYANG}|KatsuyaSuzuki{SUZUKIKATSUYA}|YukoKaneko{KANEKOYUKO}____International Concurrent Workshop 1Basic 1____Metal regulatory transcription factor 1 drives arthritis by regulating pathogenic synovialfibroblasts|An efficient functional assay platform for rheumatoid arthritis risk alleles with UNIChro-seq|Irisin mitigates rheumatoid arthritis by suppressing mitochondrial fission via inhibiting YAP-Drp1 signaling pathway|Interleukin-32-expressing CD4+ T cells are a potentially pathogenic subset in systemic sclerosis with interstitial lung disease|Rescheduled to Day 3 (April 26)

ICW1

International Concurrent Workshop 1
Basic 1

Chair：Tadashi Hosoya

KojiSuzuki{SUZUKIKOJI}|ToshimasaShimizu{SHIMIZUTOSHIMASA}|ShoichiFukui{FUKUISHOICHI}|KazunoriFuruhashi{FURUHASHIKAZUNORI}|YurieSatoh-Kanda{SATOH-KANDAYURIE}____TakahisaGono{GONOTAKAHISA}|CristinaMacía-Villa{MACÍA-VILLACRISTINA}____HidetoKameda{KAMEDAHIDETO}|KeiIkeda{IKEDAKEI}|TomonoriIshii{ISHIITOMONORI}|KosakuMurakami{MURAKAMIKOSAKU}|HyotaTakamatsu{TAKAMATSUHYOTA}|YoshiyaTanaka{TANAKAYOSHIYA}|TsutomuTakeuchi{TAKEUCHITSUTOMU}|YukoKaneko{KANEKOYUKO}|TakahisaGono{GONOTAKAHISA}|TomooKishaba{KISHABATOMOO}|TomohiroKoga{KOGATOMOHIRO}|TakeshiJohkoh{JOHKOHTAKESHI}|ReotoTakei{TAKEIREOTO}|YukoWaseda{WASEDAYUKO}|ShinjiKawaguchi{KAWAGUCHISHINJI}|ShinjiSato{SATOSHINJI}|TomoakiHoshino{HOSHINOTOMOAKI}|MasatakaKuwana{KUWANAMASATAKA}|AtsushiKawakami{KAWAKAMIATSUSHI}|TomohisaUchida{UCHIDATOMOHISA}|KunihiroIchinose{ICHINOSEKUNIHIRO}|SatoshiOhmura{OHMURASATOSHI}|DaikiNakagomi{NAKAGOMIDAIKI}|YoshiyukiAbe{ABEYOSHIYUKI}|MakotoWada{WADAMAKOTO}|NaohoTakizawa{TAKIZAWANAOHO}|AtsushiNomura{NOMURAATSUSHI}|YujiKukida{KUKIDAYUJI}|YasuhikoYamano{YAMANOYASUHIKO}|HirosukeTakagi{TAKAGIHIROSUKE}|KojiEndo{ENDOKOJI}|ShintaroHirata{HIRATASHINTARO}|NaotoAzuma{AZUMANAOTO}|TohruTakeuchi{TAKEUCHITOHRU}|KazuroKamada{KAMADAKAZURO}|RyoYanai{YANAIRYO}|YusukeMatsuo{MATSUOYUSUKE}|YasuhiroShimojima{SHIMOJIMAYASUHIRO}|RyoNishioka{NISHIOKARYO}|RyotaOkazaki{OKAZAKIRYOTA}|MayukoMoriyama{MORIYAMAMAYUKO}|AyukoTakatani{TAKATANIAYUKO}|YoshiaMiyawaki{MIYAWAKIYOSHIA}|TsuyoshiShirai{SHIRAITSUYOSHI}|HiroakiDobashi{DOBASHIHIROAKI}|IsaoMatsumoto{MATSUMOTOISAO}|ToshihikoTakada{TAKADATOSHIHIKO}|YasushiKondo{KONDOYASUSHI}|KazuotoHiramoto{HIRAMOTOKAZUOTO}|HiroyaTamai{TAMAIHIROYA}|ChihiroTakahashi{TAKAHASHICHIHIRO}|YumikoInoue{INOUEYUMIKO}|SatoshiKubo{KUBOSATOSHI}|HidenoriSakai{SAKAIHIDENORI}|RyuichiroKanda{KANDARYUICHIRO}|YuyaFujita{FUJITAYUYA}|MasanobuUeno{UENOMASANOBU}|YasuyukiTodoroki{TODOROKIYASUYUKI}|YusukeMiyazaki{MIYAZAKIYUSUKE}|IppeiMiyagawa{MIYAGAWAIPPEI}|ShingoNakayamada{NAKAYAMADASHINGO}____International Concurrent Workshop 2Connective tissue diseases 1____Serum cytokine levels in adult Still's disease: an explanatory subanalysis of a randomized controlled trial of tocilizumab|Development of a Prognostic Prediction Model for Polymyositis/Dermatomyositis-associated Interstitial Lung Disease|Relationship between anti-neutrophil cytoplasmic antibody-positivity and disease characteristics in eosinophilic granulomatosis with polyangiitis|Musculoskeletal ultrasound in patients with adult Still's disease; tendon involvement is a sign of future relapse|Stratification of Systemic Sclerosis (SSc)-associated Interstitial Lung Disease (ILD) responsive to Nintedanib (NTD) based on vascular and clinical findings

ICW2

International Concurrent Workshop 2
Connective tissue diseases 1

Chair：Takahisa Gono, Chair：Cristina Macía-Villa

MasanoriMatsumoto{MATSUMOTOMASANORI}____KeishiFujio{FUJIOKEISHI}________Luncheon Seminar 13Diagnosis and treatment of collagen disease-related TMA____Diagnosis and Treatment of Connective Tissue Disease Related TMA - Differences from Complement Mediated TMA (aHUS)-

LS13

Luncheon Seminar 13
Diagnosis and treatment of collagen disease-related TMA

【Sponsored by Alexion Pharma G.K.】

Chair：Keishi Fujio

Speaker：Masanori Matsumoto

SotaroNakajima{NAKAJIMASOTARO}|Yu-SeonJung{JUNGYU-SEON}|KyungMinKo{KOKYUNGMIN}|JinyiZhao{ZHAOJINYI}|IppeiMiyagawa{MIYAGAWAIPPEI}____MasayukiNishide{NISHIDEMASAYUKI}____HarukaTsuchiya{TSUCHIYAHARUKA}|RisaYoshihara{YOSHIHARARISA}|KazuyoshiIshigaki{ISHIGAKIKAZUYOSHI}|HarukaTakahashi{TAKAHASHIHARUKA}|TomohisaOkamura{OKAMURATOMOHISA}|KazuhikoYamamoto{YAMAMOTOKAZUHIKO}|HirokoKanda{KANDAHIROKO}|HirofumiShoda{SHODAHIROFUMI}|TetsuyaTomita{TOMITATETSUYA}|KeishiFujio{FUJIOKEISHI}|Soo-KyungCho{CHOSOO-KYUNG}|SeRimChoi{CHOISERIM}|Sun-YoungJung{JUNGSUN-YOUNG}|Yoon-KyoungSung{SUNGYOON-KYOUNG}|Su-JinMoon{MOONSU-JIN}|FengLiu{LIUFENG}|PaulBowness{BOWNESSPAUL}|LiyeChen{CHENLIYE}|ShingoNakayamada{NAKAYAMADASHINGO}|MasanobuUeno{UENOMASANOBU}|SatoshiKubo{KUBOSATOSHI}|YusukeMiyazaki{MIYAZAKIYUSUKE}|YasuyukiTodoroki{TODOROKIYASUYUKI}|YurieSatoh-Kanda{SATOH-KANDAYURIE}|YuyaFujita{FUJITAYUYA}|HidenoriSakai{SAKAIHIDENORI}|YoshiyaTanaka{TANAKAYOSHIYA}____International Concurrent Workshop 3Pathophysiology of spondyloarthritis____Plasmacytoid Dendritic Cells as Auxiliary Drivers of Axial Lesions in the Complex Pathogenesis of Spondyloarthritis|Prevalence and Drug Utilization Trends in Ankylosing Spondylitis in Korea: 2010-2023|Incidence and risk of infections in patients with ankylosing spondylitis receiving biologic therapies: A prospective observational study using the KOBIO registry|Trained immunity enhances monocyte-T-cell pathogenic crosstalk in Ankylosing Spondylitis|Effectiveness and safety of bDMARDs and JAK inhibitors for the treatment of PsA inadequate response to the first bDMARDs

ICW3

International Concurrent Workshop 3
Pathophysiology of spondyloarthritis

Chair：Masayuki Nishide

YusukeMiyazaki{MIYAZAKIYUSUKE}|HidenoriSakai{SAKAIHIDENORI}|SatsukiMatsunaga{MATSUNAGASATSUKI}|ClaudioCruciani{CRUCIANICLAUDIO}|YushoIshii{ISHIIYUSHO}____YoheiKirino{KIRINOYOHEI}____ShingoNakayamada{NAKAYAMADASHINGO}|SatoshiKubo{KUBOSATOSHI}|HiroakiTanaka{TANAKAHIROAKI}|ShunsukeFukuyo{FUKUYOSHUNSUKE}|IppeiMiyagawa{MIYAGAWAIPPEI}|NaoakiOkubo{OKUBONAOAKI}|YasuyukiTodoroki{TODOROKIYASUYUKI}|YurieSatoh-Kanda{SATOH-KANDAYURIE}|MasanobuUeno{UENOMASANOBU}|YuyaFujita{FUJITAYUYA}|HidenoriSakai{SAKAIHIDENORI}|YoshiyaTanaka{TANAKAYOSHIYA}|YusukeMiyazaki{MIYAZAKIYUSUKE}|AyakoYamaguchi{YAMAGUCHIAYAKO}|MasashiFunada{FUNADAMASASHI}|KoshiroSonomoto{SONOMOTOKOSHIRO}|MarieleGatto{GATTOMARIELE}|MartaCalatroni{CALATRONIMARTA}|GiuliaFrontini{FRONTINIGIULIA}|ClaudiaFurlan{FURLANCLAUDIA}|FrancescoReggiani{REGGIANIFRANCESCO}|ElisaBellis{BELLISELISA}|ElenaBartoloniBocci{BARTOLONIBOCCIELENA}|RossellaDeAngelis{DEANGELISROSSELLA}|CarloSalvarani{SALVARANICARLO}|MartaMosca{MOSCAMARTA}|GiacomoEmmi{EMMIGIACOMO}|MaurizioRossini{ROSSINIMAURIZIO}|FrancoFranceschini{FRANCESCHINIFRANCO}|PasqualeEsposito{ESPOSITOPASQUALE}|AlbertoCauli{CAULIALBERTO}|LeonardoCaroti{CAROTILEONARDO}|FabrizioConti{CONTIFABRIZIO}|AlessandraBortoluzzi{BORTOLUZZIALESSANDRA}|CarlomaurizioMontecucco{MONTECUCCOCARLOMAURIZIO}|PaolaFaggioli{FAGGIOLIPAOLA}|LucaIaccarino{IACCARINOLUCA}|RenatoAlbertoSinico{SINICORENATOALBERTO}|GabriellaMoroni{MORONIGABRIELLA}|AndreaDoria{DORIAANDREA}|HirokoSato{SATOHIROKO}|TsuyoshiShirai{SHIRAITSUYOSHI}|TomonoriIshii{ISHIITOMONORI}|HiroshiFujii{FUJIIHIROSHI}____International Concurrent Workshop 4Biologics for SLE____Clinical efficacy of anifrolumab and its impact on peripheral blood immune phenotypes in SLE patients with minor flares after achieving LLDAS: LOOPS Registry and FLOW Study|Impact of belimumab on immune phenotypes in patients with active lupus nephritis: LOOPS registry, FLOW study|Safety and Efficacy of Anifrolumab in Patients with Systemic Lupus Erythematosus (SLE) who Have Not Achieved LLDAS from LOOPS registry|EARLY COMBINATION WITH BELIMUMAB LEADS TO EARLIER REMISSION AND LOWER STEROID USE IN LUPUS NEPHRITIS PATIENTS: DATA FROM A REAL-LIFE MULTICENTRIC STUDY|The effectiveness of anifrolumab to systemic lupus erythematosus in single-center retrospective study

ICW4

International Concurrent Workshop 4
Biologics for SLE

Chair：Yohei Kirino

MasanobuUeno{UENOMASANOBU}|YusukeMiyazaki{MIYAZAKIYUSUKE}|ErinaYonezawa{YONEZAWAERINA}|MasaruShimizu{SHIMIZUMASARU}|KazusatoHara{HARAKAZUSATO}____HiroyaTamai{TAMAIHIROYA}____ShingoNakayamada{NAKAYAMADASHINGO}|IppeiMiyagawa{MIYAGAWAIPPEI}|KoshiroSonomoto{SONOMOTOKOSHIRO}|HiroakiTanaka{TANAKAHIROAKI}|SatoshiKubo{KUBOSATOSHI}|YusukeMiyazaki{MIYAZAKIYUSUKE}|YasuyukiTodoroki{TODOROKIYASUYUKI}|YurieSatoh-Kanda{SATOH-KANDAYURIE}|YuyaFujita{FUJITAYUYA}|HidenoriSakai{SAKAIHIDENORI}|YoshiyaTanaka{TANAKAYOSHIYA}|AtsushiNagayasu{NAGAYASUATSUSHI}|TakafumiAritomi{ARITOMITAKAFUMI}|ShunsukeFukuyo{FUKUYOSHUNSUKE}|NaoakiOkubo{OKUBONAOAKI}|MasanobuUeno{UENOMASANOBU}|JunHakamada{HAKAMADAJUN}|SatoshiTakanashi{TAKANASHISATOSHI}|HiroyaTamai{TAMAIHIROYA}|ChihiroTakahashi{TAKAHASHICHIHIRO}|YukoKaneko{KANEKOYUKO}|MistiPaudel{PAUDELMISTI}|NancyShadick{SHADICKNANCY}|MichaelE.Weinblatt{WEINBLATTMICHAELE.}|DanielSolomon{SOLOMONDANIEL}|TomohiroKoga{KOGATOMOHIRO}|ShotaKurushima{KURUSHIMASHOTA}|ToshimasaShimizu{SHIMIZUTOSHIMASA}|YukitakaUeki{UEKIYUKITAKA}|TakashiJubashi{JUBASHITAKASHI}|HiroyukiShirahige{SHIRAHIGEHIROYUKI}|AyakaUmetsu{UMETSUAYAKA}|SerinaKoto{KOTOSERINA}|TomohisaUchida{UCHIDATOMOHISA}|MizunaOtsuka{OTSUKAMIZUNA}|YoshikaTsuji{TSUJIYOSHIKA}|AyukoTakatani{TAKATANIAYUKO}|MasatakaUmeda{UMEDAMASATAKA}|ShoichiFukui{FUKUISHOICHI}|RemiSumiyoshi{SUMIYOSHIREMI}|Shin-YaKawashiri{KAWASHIRISHIN-YA}|NaokiIwamoto{IWAMOTONAOKI}|TakashiIgawa{IGAWATAKASHI}|MamiTamai{TAMAIMAMI}|TomokiOriguchi{ORIGUCHITOMOKI}|HiroshiMukae{MUKAEHIROSHI}|AtsushiKawakami{KAWAKAMIATSUSHI}____International Concurrent Workshop 5Clinical study in RA 1____Effectiveness and safety of ozoralizumab (OZR) for the treatment of RA in clinical practice -FIRST registry-|Comparison of the Efficacy and Safety of Certolizumab Pegol and Interleukin-6 Inhibitors in Patients with Rheumatoid Factor-High Rheumatoid Arthritis: Insights from the FIRST Registry|Single nucleotide polymorphisms in methotrexate metabolism affect methotrexate polyglutamates concentrations and its efficacy and safety in Patients with Rheumatoid Arthritis|Age of onset of rheumatoid arthritis and radiographic changes (Encore presentation)|Clinical association between bone destruction progression and interstitial lung disease in rheumatoid arthritis patients undergoing JAK inhibitor or CTLA4-Ig treatment

ICW5

International Concurrent Workshop 5
Clinical study in RA 1

Chair：Hiroya Tamai

ToshiyukiUshijima{USHIJIMATOSHIYUKI}|HiroyukiTeruya{TERUYAHIROYUKI}|Shin-SeokLee{LEESHIN-SEOK}|YutaInoue{INOUEYUTA}|YongFan{FANYONG}|－____SatoshiKubo{KUBOSATOSHI}|MartaMosca{MOSCAMARTA}____HiroyukiTeruya{TERUYAHIROYUKI}|TatsukiAbe{ABETATSUKI}|ManakaGoto{GOTOMANAKA}|HideyukiTakahashi{TAKAHASHIHIDEYUKI}|TakahiroItamiya{ITAMIYATAKAHIRO}|HarukaTsuchiya{TSUCHIYAHARUKA}|HirofumiShoda{SHODAHIROFUMI}|TomohisaOkamura{OKAMURATOMOHISA}|KeishiFujio{FUJIOKEISHI}|ToshiyukiUshijima{USHIJIMATOSHIYUKI}|HirofumiShouda{SHOUDAHIROFUMI}|Ji-HyounKang{KANGJI-HYOUN}|Sung-EunChoi{CHOISUNG-EUN}|Dong-JinPark{PARKDONG-JIN}|YuichiroFujieda{FUJIEDAYUICHIRO}|KenichiMiyamoto{MIYAMOTOKENICHI}|KazuroKamada{KAMADAKAZURO}|YotaroOki{OKIYOTARO}|MitsutakaYasuda{YASUDAMITSUTAKA}|HarukaMoriya{MORIYAHARUKA}|YukiKudo{KUDOYUKI}|ShuheiTakeyama{TAKEYAMASHUHEI}|RyoHisada{HISADARYO}|MichihitoKono{KONOMICHIHITO}|OlgaAmengual{AMENGUALOLGA}|TatsuyaAtsumi{ATSUMITATSUYA}|YanGeng{GENGYAN}|XiaofeiYe{YEXIAOFEI}|JuanZhao{ZHAOJUAN}|HongHuang{HUANGHONG}|JiayingZhang{ZHANGJIAYING}|XiaohuiZhang{ZHANGXIAOHUI}|ZhuoliZhang{ZHANGZHUOLI}____International Concurrent Workshop 6Pathophysiology of SLE 1____The involvement of IGHV4-34 in the pathogenesis of systemic lupus erythematosus|Single-cell RNA-seq-based analysis of newly identified age-associated ThA cells in the pathogenesis of systemic lupus erythematosus|Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study|Development of a Semi-Quantitative Lupus Anticoagulant Assay and Its Application in Thrombosis Risk Assessment for Antiphospholipid Syndrome|Single-cell RNA sequencing reveals cross-disease characterizations of treatment-naïve autoimmune diseases and distinct interferon signatures in systemic lupus erythematosus|Withdrawn

ICW6

International Concurrent Workshop 6
Pathophysiology of SLE 1

Chair：Satoshi Kubo, Chair：Marta Mosca

EiichiTanaka{TANAKAEIICHI}____ShigekiMomohara{MOMOHARASHIGEKI}________Luncheon Seminar 14Treatment of rheumatoid arthritis from the perspective of medical economics____Treatment of rheumatoid arthritis from the perspective of medical economics

LS14

Luncheon Seminar 14
Treatment of rheumatoid arthritis from the perspective of medical economics

【Sponsored by NIPPON KAYAKU CO.,LTD./Celltrion Healthcare japan K.K】

Chair：Shigeki Momohara

Speaker：Eiichi Tanaka

ShogoMatsuda{MATSUDASHOGO}|KoichiSaito{SAITOKOICHI}|MuneyukiHatta{HATTAMUNEYUKI}|HiroyaTamai{TAMAIHIROYA}|－____KunihikoUmekita{UMEKITAKUNIHIKO}|DennisG.Mcgonagle{MCGONAGLEDENNISG.}____TakuyaKotani{KOTANITAKUYA}|KatsumasaOe{OEKATSUMASA}|ChifumiAkiyama{AKIYAMACHIFUMI}|MahiroYamamoto{YAMAMOTOMAHIRO}|TakayasuSuzuka{SUZUKATAKAYASU}|RanNakashima{NAKASHIMARAN}|HideakiTsuji{TSUJIHIDEAKI}|TsuneoSasai{SASAITSUNEO}|YasuhiroNohda{NOHDAYASUHIRO}|TsuneyasuYoshida{YOSHIDATSUNEYASU}|YoichiNakayama{NAKAYAMAYOICHI}|YutoNakakubo{NAKAKUBOYUTO}|AtsubumiOgawa{OGAWAATSUBUMI}|KazumaYoshida{YOSHIDAKAZUMA}|KeisukeHirobe{HIROBEKEISUKE}|YukiAitani{AITANIYUKI}|YudaiKoshida{KOSHIDAYUDAI}|HirofumiMiyake{MIYAKEHIROFUMI}|TohruTakeuchi{TAKEUCHITOHRU}|MitsuhiroAkiyama{AKIYAMAMITSUHIRO}|KeikoYoshimoto{YOSHIMOTOKEIKO}|NoriyasuSeki{SEKINORIYASU}|HiroshiTakei{TAKEIHIROSHI}|YasushiKondo{KONDOYASUSHI}|JunKikuchi{KIKUCHIJUN}|YukoKaneko{KANEKOYUKO}|MayuShiomi{SHIOMIMAYU}|RyuWatanabe{WATANABERYU}|YuichiMasuda{MASUDAYUICHI}|AyanaOkazaki{OKAZAKIAYANA}|ShogoMatsuda{MATSUDASHOGO}|MikihitoShoji{SHOJIMIKIHITO}|RyosukeTsuge{TSUGERYOSUKE}|RyosukeHiwa{HIWARYOSUKE}|NaokoIto{ITONAOKO}|YouheiFujiki{FUJIKIYOUHEI}|WataruYamamoto{YAMAMOTOWATARU}|MotomuHashimoto{HASHIMOTOMOTOMU}|SoraIto{ITOSORA}|SatoshiTakanashi{TAKANASHISATOSHI}____International Concurrent Workshop 7Other than rheumatic disease 1____Risk prediction model for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies in multicenter MYKO cohort study|Naive B cells as key pathogenic contributors to interleukin-6 production in idiopathic multicentric Castleman's disease|Granulomatosis with polyangiitis (GPA) associated with MPO-ANCA and PR3-ANCA exhibits distinct clinical courses - Data from the REVEAL cohort|Achievement and Usefulness of Intermediate Treatment Targets for Still's Disease Proposed by EULAR/PReS|Withdrawn

ICW7

International Concurrent Workshop 7
Other than rheumatic disease 1

Chair：Kunihiko Umekita, Chair：Dennis G. Mcgonagle

YasuoNagafuchi{NAGAFUCHIYASUO}|MasahiroNakano{NAKANOMASAHIRO}|YujieSong{SONGYUJIE}|YujingLi{LIYUJING}|AlaaTerukawa{TERUKAWAALAA}____RyuWatanabe{WATANABERYU}____MasahiroNakano{NAKANOMASAHIRO}|MinetoOta{OTAMINETO}|HiroakiHatano{HATANOHIROAKI}|HarukaTakahashi{TAKAHASHIHARUKA}|TakahiroItamiya{ITAMIYATAKAHIRO}|TomohisaOkamura{OKAMURATOMOHISA}|KeishiFujio{FUJIOKEISHI}|KazuyoshiIshigaki{ISHIGAKIKAZUYOSHI}|MasatakaUmeda{UMEDAMASATAKA}|TakayukiKatsuyama{KATSUYAMATAKAYUKI}|AyukoTakatani{TAKATANIAYUKO}|HiroshiKajiyama{KAJIYAMAHIROSHI}|RyusukeYoshimi{YOSHIMIRYUSUKE}|YusukeMatsuo{MATSUOYUSUKE}|YasuhiroShimojima{SHIMOJIMAYASUHIRO}|TakashiKida{KIDATAKASHI}|NobuyukiYajima{YAJIMANOBUYUKI}|NobuyaAbe{ABENOBUYA}|KodaiSakiyama{SAKIYAMAKODAI}|YuichiroFujieda{FUJIEDAYUICHIRO}|YutaInoue{INOUEYUTA}|KenichiMiyamoto{MIYAMOTOKENICHI}|KazuroKamada{KAMADAKAZURO}|YotaroOki{OKIYOTARO}|MitsutakaYasuda{YASUDAMITSUTAKA}|HarukaMoriya{MORIYAHARUKA}|ShuheiTakeyama{TAKEYAMASHUHEI}|RyoHisada{HISADARYO}|MichihitoKono{KONOMICHIHITO}|OlgaAmengual{AMENGUALOLGA}|TatsuyaAtsumi{ATSUMITATSUYA}|MinglongCai{CAIMINGLONG}|ZhuChen{CHENZHU}____International Concurrent Workshop 8Basic 2____T cell plasticity in systemic lupus erythematosus revealed by large-scale T cell receptor repertoire and transcriptome studies|Disease-specific genetic risk variants revealed by case-case GWAS contribute to disease-specific clinical manifestations of SLE and RA|Functional Connectivity Associated with Fatigue in Systemic Lupus Erythematosus: A Resting-State Functional MRI Study|MTHFD2 promotes osteoclastogenesis and bone loss in rheumatoid arthritis by enhancing CKMT1-dependent oxidative phosphorylation|Blockade of Cellular Communication Network Factor 3 suppresses pathological process of rheumatoid arthritis through inhibiting cell senescence and osteoclastogenesis in the joint

ICW8

International Concurrent Workshop 8
Basic 2

Chair：Ryu Watanabe

KokinSon{SONKOKIN}|EvanPollock-Tahiri{POLLOCK-TAHIRIEVAN}|ReonaTanimura{TANIMURAREONA}|JinghuiYu{YUJINGHUI}|ShoSendo{SENDOSHO}|Deng-HoYang{YANGDENG-HO}____YuyaKondo{KONDOYUYA}____MasaoKatsushima{KATSUSHIMAMASAO}|RyuWatanabe{WATANABERYU}|RyuheiIshihara{ISHIHARARYUHEI}|YuheiFujisawa{FUJISAWAYUHEI}|KazuoFukumoto{FUKUMOTOKAZUO}|ShinsukeYamada{YAMADASHINSUKE}|RanNakashima{NAKASHIMARAN}|MotomuHashimoto{HASHIMOTOMOTOMU}|AncaMaglaviceanu{MAGLAVICEANUANCA}|JasonS.Rockel{ROCKELJASONS.}|HelenaFetterFilippini{FETTERFILIPPINIHELENA}|EwaWasilewski{WASILEWSKIEWA}|MelissaM.Lewis-Bakker{LEWIS-BAKKERMELISSAM.}|ShabanaVohra{VOHRASHABANA}|RachelE.Miller{MILLERRACHELE.}|KatrinaHueniken{HUENIKENKATRINA}|OsvaldoEspin-Garcia{ESPIN-GARCIAOSVALDO}|ChiaraPastrello{PASTRELLOCHIARA}|PratibhaPotla{POTLAPRATIBHA}|YangqingDeng{DENGYANGQING}|KeemoDelosSantos{DELOSSANTOSKEEMO}|StarleeLively{LIVELYSTARLEE}|NikitaLooby{LOOBYNIKITA}|JohanaGarcia{GARCIAJOHANA}|BehdadRavarian{RAVARIANBEHDAD}|LauraBennett{BENNETTLAURA}|JianWang{WANGJIAN}|MichaelFehlings{FEHLINGSMICHAEL}|Anne-MarieMalfait{MALFAITANNE-MARIE}|RajivGandhi{GANDHIRAJIV}|NizarN.Mahomed{MAHOMEDNIZARN.}|TimothyLeroux{LEROUXTIMOTHY}|IgorJurisica{JURISICAIGOR}|LakshmiP.Kotra{KOTRALAKSHMIP.}|RobertP.Bonin{BONINROBERTP.}|HanceClarke{CLARKEHANCE}|MohitKapoor{KAPOORMOHIT}|YuyaKondo{KONDOYUYA}|RyotaSato{SATORYOTA}|RyoheiNishino{NISHINORYOHEI}|MasaruShimizu{SHIMIZUMASARU}|HiromitsuAsashima{ASASHIMAHIROMITSU}|HarukaMiki{MIKIHARUKA}|HirotoTsuboi{TSUBOIHIROTO}|TakayukiSumida{SUMIDATAKAYUKI}|IsaoMatsumoto{MATSUMOTOISAO}|RyoHatano{HATANORYO}|YoshiyukiAbe{ABEYOSHIYUKI}|KeiOhnuma{OHNUMAKEI}|ChikaoMorimoto{MORIMOTOCHIKAO}|AlfonsoDelPeralFanjul{DELPERALFANJULALFONSO}|KazumaNishisaka{NISHISAKAKAZUMA}|HirotakaYamada{YAMADAHIROTAKA}|TakaichiOkano{OKANOTAKAICHI}|KeisukeNishimura{NISHIMURAKEISUKE}|YoUeda{UEDAYO}|JunSaegusa{SAEGUSAJUN}____International Concurrent Workshop 9Basic Animal Model 1____Evaluation of the role of anti-IL-17A Treatment for Kidney and Lung Damage in a Pristane-Induced Lupus Model|Oral delivery of delta-9-tetrahydrocannabinol has pain-modifying effects in mouse models of knee osteoarthritis|Pathogenetic role of IFNg producing CD4+ T cells in IMQ-induced lupus model mice|Interleukin-26 as a potential therapeutic target in an antigen-induced arthritis model|Upregulated Neddylation in Arthritic SKG mice: A Potential Therapeutic Target for Arthritis|The anti-inflammatory effect of theaflavins in a murine model of collagen-induced arthritis

ICW9

International Concurrent Workshop 9
Basic Animal Model 1

Chair：Yuya Kondo

TsuneoSasai{SASAITSUNEO}|YeJiJung{JUNGYEJI}|GhangByeongzu{BYEONGZUGHANG}|HongHuang{HUANGHONG}|AnnieRoseA.Ammar{AMMARANNIEROSEA.}____YasushiKondo{KONDOYASUSHI}|Marie-ChristopheBoissier{BOISSIERMARIE-CHRISTOPHE}____RanNakashima{NAKASHIMARAN}|TsuneyasuYoshida{YOSHIDATSUNEYASU}|KiminobuTanizawa{TANIZAWAKIMINOBU}|MireiShirakashi{SHIRAKASHIMIREI}|RyosukeHiwa{HIWARYOSUKE}|HideakiTsuji{TSUJIHIDEAKI}|ShujiAkizuki{AKIZUKISHUJI}|HajimeYoshifuji{YOSHIFUJIHAJIME}|AkioMorinobu{MORINOBUAKIO}|CheolhoHeo{HEOCHEOLHO}|Yong-DaeKwon{KWONYONG-DAE}|SuJinJeong{JEONGSUJIN}|Seung-JaeHong{HONGSEUNG-JAE}|JiwonHwang{HWANGJIWON}|Yeon-AhLee{LEEYEON-AH}|JiSungLee{LEEJISUNG}|BinYoo{YOOBIN}|Yong-GilKim{KIMYONG-GIL}|JongHanChoi{CHOIJONGHAN}|HyunJungKim{KIMHYUNJUNG}|ZhuoliZhang{ZHANGZHUOLI}|LeandroJoseA.Dado{DADOLEANDROJOSEA.}|RicaKeziaP.King{KINGRICAKEZIAP.}|BrigitteAizaD.Yu-Lao{YU-LAOBRIGITTEAIZAD.}|AileenU.Agbanlog{AGBANLOGAILEENU.}|GeraldineT.Zamora{ZAMORAGERALDINET.}____International Concurrent Workshop 10Comobities____Prognostic Value of AI-Based Quantitative CT in Anti-MDA5 Antibody-Associated ILD: A Longitudinal Study of CT Pattern Changes|Increased Risk of Medication-Related Osteonecrosis of the Jaw in Rheumatologic Patients Treated with Denosumab Following Intravenous Bisphosphonate Therapy|Associations between Cardiovascular Risk and Seropositive Rheumatoid Arthritis|Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: evidence from the prospective CENTRA cohort|Clinical profile and Outcomes of Patients with Immune-related Adverse Events to Immune Checkpoint Inhibitors

ICW10

International Concurrent Workshop 10
Comobities

Chair：Yasushi Kondo, Chair：Marie-Christophe Boissier

HiroakiDobashi{DOBASHIHIROAKI}____YukoKaneko{KANEKOYUKO}____YusukeUshio{USHIOYUSUKE}____Luncheon Seminar 15Treatment Strategies for Pulmonary Lesions Complicated by CTD____Treatment Strategies for Pulmonary Lesions Complicated by CTD

LS15

Luncheon Seminar 15
Treatment Strategies for Pulmonary Lesions Complicated by CTD

【Sponsored by Nippon Boehringer Ingelheim Co., Ltd.】

Chair：Yuko Kaneko

Speaker：Hiroaki Dobashi

MasaoKatsushima{KATSUSHIMAMASAO}|YukiEtani{ETANIYUKI}|SatsukiMatsunaga{MATSUNAGASATSUKI}|AkiraOnishi{ONISHIAKIRA}|YusukeYoshida{YOSHIDAYUSUKE}____ShujiSumitomo{SUMITOMOSHUJI}|GerdR.Burmester{BURMESTERGERDR.}____YuheiFujisawa{FUJISAWAYUHEI}|RyuheiIshihara{ISHIHARARYUHEI}|TakahitoKojima{KOJIMATAKAHITO}|YutaroYamada{YAMADAYUTARO}|KenjiMamoto{MAMOTOKENJI}|TadashiOkano{OKANOTADASHI}|AkiraOnishi{ONISHIAKIRA}|KosakuMurakami{MURAKAMIKOSAKU}|YasutakaOkita{OKITAYASUTAKA}|HirotakaYamada{YAMADAHIROTAKA}|ShinyaHayashi{HAYASHISHINYA}|HideyukiShiba{SHIBAHIDEYUKI}|TakuyaKotani{KOTANITAKUYA}|HidekiAmuro{AMUROHIDEKI}|YonsuSon{SONYONSU}|TetsuItami{ITAMITETSU}|YujiNozaki{NOZAKIYUJI}|WataruYamamoto{YAMAMOTOWATARU}|TomohiroKuwamoto{KUWAMOTOTOMOHIRO}|YuyaYano{YANOYUYA}|TasukuTogashi{TOGASHITASUKU}|KazuoFukumoto{FUKUMOTOKAZUO}|RyuWatanabe{WATANABERYU}|ShinsukeYamada{YAMADASHINSUKE}|MotomuHashimoto{HASHIMOTOMOTOMU}|KosukeEbina{EBINAKOSUKE}|YuichiMaeda{MAEDAYUICHI}|KoheiTsujimoto{TSUJIMOTOKOHEI}|HideoOnizawa{ONIZAWAHIDEO}|TakaichiOkano{OKANOTAKAICHI}|KeisukeNishimura{NISHIMURAKEISUKE}|AyakaYoshikawa{YOSHIKAWAAYAKA}|RyotaHara{HARARYOTA}|AtsushiKumanogoh{KUMANOGOHATSUSHI}|SeijiOkada{OKADASEIJI}|ShingoNakayamada{NAKAYAMADASHINGO}|YusukeMiyazaki{MIYAZAKIYUSUKE}|NaoakiOhkubo{OHKUBONAOAKI}|SatoshiKubo{KUBOSATOSHI}|KoshiroSonomoto{SONOMOTOKOSHIRO}|IppeiMiyagawa{MIYAGAWAIPPEI}|YurieSatoh-Kanda{SATOH-KANDAYURIE}|HiroakiTanaka{TANAKAHIROAKI}|YasuyukiTodoroki{TODOROKIYASUYUKI}|MasanobuUeno{UENOMASANOBU}|AtsushiNagayasu{NAGAYASUATSUSHI}|YuyaFujita{FUJITAYUYA}|HidenoriSakai{SAKAIHIDENORI}|YoshiyaTanaka{TANAKAYOSHIYA}|MasaoTanaka{TANAKAMASAO}|ShuichiroNakabo{NAKABOSHUICHIRO}|KoichiMurata{MURATAKOICHI}|TakayukiFujii{FUJIITAKAYUKI}|IkuShirasugi{SHIRASUGIIKU}|MasaoKatsushima{KATSUSHIMAMASAO}|ShuichiMatsuda{MATSUDASHUICHI}|AkioMorinobu{MORINOBUAKIO}|HirokiKohno{KOHNOHIROKI}|MichinoriIshitoku{ISHITOKUMICHINORI}|HirofumiWatanabe{WATANABEHIROFUMI}|TadahiroTokunaga{TOKUNAGATADAHIRO}|TomohiroSugimoto{SUGIMOTOTOMOHIRO}|ShoMokuda{MOKUDASHO}|TakakiNojima{NOJIMATAKAKI}|TetsuOyama{OYAMATETSU}|EijiSugiyama{SUGIYAMAEIJI}|ShintaroHirata{HIRATASHINTARO}____International Concurrent Workshop 11Clinical study in RA 2____Real-world comparative effects of IL-6 inhibitors on HbA1c in patients with rheumatoid arthritis: The ANSWER Cohort Study|Impact of seropositivity on drug retention of biologics and JAK inhibitors: the ANSWER cohort study|Treatment Strategies for Pregnancy in Women of Childbearing Age (WoCBA) Rheumatoid Arthritis (RA) Patients with High Disease Activity: Insights from the FIRST registry|Heterogeneous treatment effects of biological DMARD versus JAK inhibitor on disease activity in patients with rheumatoid arthritis: the ANSWER cohort study|Differences in responsiveness of composite measures and their components reflecting disease activity over initial therapy in early rheumatoid arthritis: a post-hoc analysis of a multicenter cohort study

ICW11

International Concurrent Workshop 11
Clinical study in RA 2

Chair：Shuji Sumitomo, Chair：Gerd R. Burmester

YoichiNakayama{NAKAYAMAYOICHI}|TaikiYamaguchi{YAMAGUCHITAIKI}|TakafumiAritomi{ARITOMITAKAFUMI}|TakayukiFujii{FUJIITAKAYUKI}|WenhuiXie{XIEWENHUI}____Jun-IchiFukushi{FUKUSHIJUN-ICHI}|TomW.Huizinga{HUIZINGATOMW.}____RanNakashima{NAKASHIMARAN}|KiminobuTanizawa{TANIZAWAKIMINOBU}|KosakuMurakami{MURAKAMIKOSAKU}|AkiraOnishi{ONISHIAKIRA}|TakayukiFujii{FUJIITAKAYUKI}|TomoyaNakajima{NAKAJIMATOMOYA}|TsuneyasuYoshida{YOSHIDATSUNEYASU}|SoheiFunakoshi{FUNAKOSHISOHEI}|AkikoYoshida{YOSHIDAAKIKO}|KoichiMurata{MURATAKOICHI}|MasaoTanaka{TANAKAMASAO}|MireiShirakashi{SHIRAKASHIMIREI}|RyosukeHiwa{HIWARYOSUKE}|HideakiTsuji{TSUJIHIDEAKI}|ShujiAkizuki{AKIZUKISHUJI}|HajimeYoshifuji{YOSHIFUJIHAJIME}|MotomuHashimoto{HASHIMOTOMOTOMU}|AkioMorinobu{MORINOBUAKIO}|TadashiHosoya{HOSOYATADASHI}|HirokazuSasaki{SASAKIHIROKAZU}|AkioYamamoto{YAMAMOTOAKIO}|NatsukaUmezawa{UMEZAWANATSUKA}|HisanoriHasegawa{HASEGAWAHISANORI}|NaokiKimura{KIMURANAOKI}|TetsuyaSaito{SAITOTETSUYA}|HideyukiIwai{IWAIHIDEYUKI}|RyujiKoike{KOIKERYUJI}|YutaKochi{KOCHIYUTA}|ShinsukeYasuda{YASUDASHINSUKE}|KoshiroSonomoto{SONOMOTOKOSHIRO}|ShingoNakayamada{NAKAYAMADASHINGO}|HiroakiTanaka{TANAKAHIROAKI}|SatoshiKubo{KUBOSATOSHI}|IppeiMiyagawa{MIYAGAWAIPPEI}|AyakoYamaguchi{YAMAGUCHIAYAKO}|NaoakiOkubo{OKUBONAOAKI}|MasanobuUeno{UENOMASANOBU}|YoshiyaTanaka{TANAKAYOSHIYA}|ShuichiroNakabo{NAKABOSHUICHIRO}|ShuichiMatsuda{MATSUDASHUICHI}____International Concurrent Workshop 12Clinical study in RA 3____Lung-Joint Associations: AI-Based CT Analysis Reveals Distinct Lung Patterns Predicting Rheumatoid Arthritis Outcomes|Polygenic score analysis of refractory rheumatoid arthritis patients|The effect of biologic/targeted synthetic DMARDs on bone mineral density of patients with rheumatoid arthritis: a five-year observation from FIRST registry|Psychological Changes in Rheumatoid Arthritis Patients After Achieving Treatment Goals with b/tsDMARDs: A Longitudinal KURAMA Cohort Study|Current practice, trends and attitudes of rheumatologists towards glucocorticoids use for rheumatoid arthritis (GURANTEE): a national cross-sectional survey across China

ICW12

International Concurrent Workshop 12
Clinical study in RA 3

Chair：Jun-Ichi Fukushi, Chair：Tom W. Huizinga

MasaakiMori{MORIMASAAKI}____－________Meet the Expert 1Characteristics of juvenile idiopathic arthritis (JIA) that differ from rheumatoid arthritis -Focusing on synthetic antirheumatic drugs and biological agents available in Japan-____Characteristics of juvenile idiopathic arthritis (JIA) that differ from rheumatoid arthritis -Focusing on synthetic antirheumatic drugs and biological agents available in Japan-

MTE1

Meet the Expert 1
Characteristics of juvenile idiopathic arthritis (JIA) that differ from rheumatoid arthritis -Focusing on synthetic antirheumatic drugs and biological agents available in Japan-

Lecturer：Masaaki Mori

MasatakaKuwana{KUWANAMASATAKA}____－________Meet the Expert 2SSc Quiz: Basic knowledge on SSc management____SSc Quiz: Basic knowledge on SSc management

MTE2

Meet the Expert 2
SSc Quiz: Basic knowledge on SSc management

Lecturer：Masataka Kuwana

AyumiShintani{SHINTANIAYUMI}____－________Meet the Expert 3Statistical Method for Analyzing Repeatedly Measured Data____Statistical Method for Analyzing Repeatedly Measured Data

MTE3

Meet the Expert 3
Statistical Method for Analyzing Repeatedly Measured Data

Lecturer：Ayumi Shintani

TakahiroUshida{USHIDATAKAHIRO}____－________Meet the Expert 4Classification and treatment of chronic pain____Classification and treatment of chronic pain

MTE4

Meet the Expert 4
Classification and treatment of chronic pain

Lecturer：Takahiro Ushida

MitsumasaKishimoto{KISHIMOTOMITSUMASA}____－________Meet the Expert 5History taking and physical examination in the patient with arthralgia and arthritis____History taking and physical examination in the patient with arthralgia and arthritis

MTE5

Meet the Expert 5
History taking and physical examination in the patient with arthralgia and arthritis

Lecturer：Mitsumasa Kishimoto

HiroakiUmebayashi{UMEBAYASHIHIROAKI}____－________Meet the Expert 6Preparing for Rheumatology Treatment in Times of Disaster____Preparing for Rheumatology Treatment in Times of Disaster

MTE6

Meet the Expert 6
Preparing for Rheumatology Treatment in Times of Disaster

Lecturer：Hiroaki Umebayashi

YoshiyaTanaka{TANAKAYOSHIYA}____－________Meet the Expert 7Precision medicine in rheumatic diseases: How to differentially select targeted therapies?____Precision medicine in rheumatic diseases: How to differentially select targeted therapies?

MTE7

Meet the Expert 7
Precision medicine in rheumatic diseases: How to differentially select targeted therapies?

Lecturer：Yoshiya Tanaka

TatsuyaAtsumi{ATSUMITATSUYA}____－________Meet the Expert 8Management of the antiphospholipid syndrome: AtoZ____Management of the antiphospholipid syndrome: AtoZ

MTE8

Meet the Expert 8
Management of the antiphospholipid syndrome: AtoZ

Lecturer：Tatsuya Atsumi

NaotoTamura{TAMURANAOTO}____－________Meet the Expert 9Appropriate knowledge for management of axial spondyloarthritis____Appropriate knowledge for management of axial spondyloarthritis

MTE9

Meet the Expert 9
Appropriate knowledge for management of axial spondyloarthritis

Lecturer：Naoto Tamura

NatsukoNakagawa{NAKAGAWANATSUKO}____－________Meet the Expert 10RA Hand Surgery____RA Hand Surgery

MTE10

Meet the Expert 10
RA Hand Surgery

Lecturer：Natsuko Nakagawa

HidekataYasuoka{YASUOKAHIDEKATA}____－________Meet the Expert 11The basics of physical examination for skin thickening in scleroderma____The basics of physical examination for skin thickening in scleroderma

MTE11

Meet the Expert 11
The basics of physical examination for skin thickening in scleroderma

Lecturer：Hidekata Yasuoka

IsaoMatsumoto{MATSUMOTOISAO}____－________Meet the Expert 12Topics on synovial lesions and immune pathology in RA____Topics on synovial lesions and immune pathology in RA

MTE12

Meet the Expert 12
Topics on synovial lesions and immune pathology in RA

Lecturer：Isao Matsumoto

－____－________Hands-on Seminar 1____－

HS1

Hands-on Seminar 1

－____－________General Assembly____－

NO01

General Assembly

－____－________Society Prize for Encouragement Lecture____－

NO02

Society Prize for Encouragement Lecture

－____－________Welcome PartyAward Celemony for Future Rheumatology____－

NO04

Welcome Party
Award Celemony for Future Rheumatology

－____－________Exhibition____－

NO05

Exhibition

YuMunakata{MUNAKATAYU}____ToshihideMimura{MIMURATOSHIHIDE}________[Live Video Proceedings] Educational Lecture 6____－

EL6_S

[Live Video Proceedings] Educational Lecture 6